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 Regulatory agencies around the world conduct assessments to determine the 
potential for chemicals to pose a threat to human-health. These assessments typically 
consist of a critical review of available studies to identify adverse health effects of 
chemicals and to characterize exposure-response relationships. Recent reviews of these 
assessments have called for greater transparency of the process used and decisions made. 
In addition, advances in methodologies such as the systematic review of studies, and 
advances in science such as high-throughput screening data, may improve the 
conclusions of an assessment, but may further complicate development and presentation.    
In this project, we aimed at addressing these challenges by creating a modular content-
management system designed to synthesize multiple data sources into overall human 
health assessments of chemicals. First, a list of modules and requirements were identified 
for the creation of a web-based workspace.  Next, we created an online prototype using 
these requirements, HAWC (Health Assessment Workspace Collaborative, 
https://hawcproject.org/). This online application documents overall workflow of 
assessment creation, from literature search and systematic-review, to data extraction, 
dose-response analysis, evidence synthesis, uncertainty characterization, and finally the 
 iii 
creation of customized reports. Finally, completed and ongoing assessments were entered 
into HAWC to better understand the potential and limitations of the design. Overall, this 
project creates a clear and concise summary of the results of the assessment, provides a 
workspace for teams to collaborate on ongoing assessments, and enhances transparency 
by providing online access to the data and scientific decisions used to drive the 
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Risk assessment methodology 
Human exposures to chemicals in the environment are frequent and have the 
potential to cause adverse health effects. A commonly method to evaluate the potential 
for harm by regulatory agencies is the use of a risk assessment. Key steps in the risk 
assessment process from hazard identification to risk management as classically defined 
by the National Resource Council’s "Red Book" (National Research Council 1983).  
While the framework for these assessments has remained constant over the last three-
decades, they’re conducted using the latest available data, knowledge, and approved 
methodologies (U. S. EPA 2004). 
The risk assessment process includes four key steps: hazard identification, dose-
response assessment, exposure assessment, and risk characterization (National Research 
Council 1983). Hazard identification is defined as the process to determine whether a 
chemical is causally linked to a particular health effect, while dose-response assessment 
is the process of determining the magnitude of exposure and occurrence of health effect. 
Based on today’s implementation of the process, these two steps are commonly 
performed together, and the results may be applied to a particular exposure scenario. The 
exposure assessment process is the determination of the extent of human exposure. 
Finally, risk characterization is the process description and magnitude of human risk, 
which combines the exposure assessment with results from the dose-response assessment 
to determine how many and to what extent people may have been affected. Uncertainty 
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and variability may be propagated through the dose-response and exposure-assessment, 
and should be included in the risk characterization. Ultimately, the results from a risk 
assessment can be used for risk management, which shifts from the scientific domain to 
the regulatory domain, weighing policy alternative to manage health risks with other 
considerations such as financial cost, economic profits, and other social and political 
considerations. 
The risk assessment methodology was further advanced with the 2009 release of 
the National Academy of Sciences (NAS) "Silver Book": Science and Decisions: 
Advancing Risk Assessment (National Research Council 2009). Key recommendations 
included unifying the response approach for cancer and non-cancer effects (including 
low-dose nonlinearity effects), and accounting for uncertainty and variability in all 
computational steps of the assessment. In addition, recommendations for increased 
stakeholder involvement during the development process of the risk-assessment were also 
recommended, as well as capacity-building programs to produce a greater number of 
assessments of higher quality. 
Application of benchmark-dose modeling 
A goal of the dose-response assessment is to produce a numerical value where 
exposure at or below this level over a specified period of time is expected to produce no 
or minimal adverse health risks. The point-of-departure (POD) is a dose which is 
associated with an adverse health outcome, which is frequently divided by uncertainty 
factors (UF) to calculate a reference dose (RfD), which is the dose expected to produce 
lower or minimal health-risks. When using animal bioassay data, where studies include 
multiple animals dosed at increasing concentrations, No Adverse Effect Level (NOAEL) 
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or Lowest Adverse Effect Level (LOAEL) are frequently estimated and may be used as a 
POD. The NOAEL is the maximum dose where no significant change from control was 
found for a given phenotype, while a LOAEL is the minimum dose where a significant 
change in control was found.  
Instead of being restricted to the dose-level studied in the experiment, the 
benchmark dose-modeling approach (BMD) can be applied (Crump 1984). If the 
relationship between dose and response is modeled, then a benchmark dose (BMD) can 
be estimated at any benchmark response (BMR) level of interest, which is predefined by 
the user. For example, a BMR may be defined as a ten percent increase in incidence from 
control, or a one-standard deviation increase in mean response. A lower-confidence level 
benchmark dose (BMDL) can also be estimated, which represents a lower-confidence 
dose associated with a BMR, and is frequently used as a point-of-departure. A summary 
of potential points-of-departure for a study are shown below in Figure 1. 
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Figure 1: Example dose-response dataset with key terminology and application for risk assessment labeled. 
Figure adapted from Crump et al. 2010. 
 
 
There are advantages to the use of selection of a BMDL as a point-of-departure, 
in contrast with the use of a NOAEL or LOAEL. Frist, NOAEL/LOAELs are limited to 
the doses tested in the study, do not capture information about the shape of the dose-
response curve, and may not capture the true dose related to an effect (e.g., if a NOAEL 
is the highest dose examined, it might not be a true NOAEL) (Barnes and Dourson 1988; 
Travis et al. 2005). Further, the BMR selected for BMD/BMDL estimation can be set to a 
biologically-relevant level, in contrast to NOAEL/LOAEL which is based solely on 
statistical-difference from control response. Finally, with more uncertainty in a dose-
response trend, a higher dose-may selected as a LOAEL or NOAEL, as there is less 
statistical difference from control, while a lower BMDL will be estimated due to various 
model fits, thus calculating a more conservative POD with more uncertainty in the data. 
Chapter 1: Literature Review 
5 
Risk assessment in practice 
There are multiple regulatory agencies (as well as for-profit businesses) which 
conduct risk assessments, each process is slightly different. In practice, not all risk 
assessments include all four steps described above, and it is frequently the case that only 
hazard identification and optionally dose-response assessments are performed on a 
chemical-by-chemical basis. Descriptions of the risk assessment methodology applied by 
practitioners at the federal, state, and international level are detailed below. 
Federally in the US 
The US EPA is frequently tasked for determining allowable emissions or release 
rates for chemicals in the environment through legislation such as the Clean Air Act (42 
U.S. Code § 7401) or Safe Drinking Water Act (42 U.S. Code § 300f), or to propose 
cleanup levels at contaminated sites (42 U.S. Code § 9601). To estimate safe levels of 
chemicals, the EPA has created the Integrated Risk Information System (IRIS), which is 
a database of comprehensive chemical-specific reports of the hazard identifications and 
dose-response assessment portions of the risk assessment process. 
For non-cancer effects, an IRIS assessment reports a Reference Dose (RfD), 
which is the dose at which chronic exposure over 70 years is not likely to be associated 
with adverse health effects (Barnes and Dourson 1988). The RfD value is derived from 
identifying a point-of-departure (POD), which is an adverse health effect, and the 
application of uncertainty factors (UF) to reflect uncertainty and variability in this 
estimate. For inhaled chemicals, a Reference Concentration (RfC) can similarly be 
derived. 
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For cancer effects, IRIS assessments may also derive an oral slope factor (OSF), 
which represents the change in risk of cancer with a lifetime average-daily dose of a 
chemical (U. S. EPA 2005a). Similarly, an Inhalation Unit Risk (IUR) factor may be 
derived for the appreciable risk from inhalation of a chemical for a lifetime. A key 
process in the revised 2005 EPA cancer guidelines includes establishing a mode of action 
(MOA), or "a sequence of key events and processes, starting with the interaction of an 
agent with a cell, proceeding through operational and anatomical changes, and resulting 
in cancer formulation" (U. S. EPA 2005a). If a MOA cannot be determined or may have a 
low-dose linear dose-response and non-mutagenic MOA, then a linear extrapolation can 
be used to develop a cancer potency factor. Otherwise, benchmark dose-modeling can be 
used for determination of a cancer potency factor. In addition, administered doses are 
scaled to mg/kg
3/4
-d for animal studies, on the basis of dose-scaling from animals to 
humans (U. S. EPA 2005a). 
The IRIS process is expected to take between 24-36 months for completion of an 
assessment (U. S. EPA 2013a), though it is frequently the case that assessments may take 
multiple years or even decades for final release (Gray and Cohen 2012). The assessments 
go through multiple rounds of internal, inter-agency, and external review. A detailed 
literature search is performed to ensure that the current state- of the science is captured, 
including relevant toxicological, epidemiological, and mechanistic information regarding 
toxicity of chemicals. Draft IRIS assessments undergo considerable review; for key 
assessments of frequently used chemicals the National Research Council (NRC) may 
perform an independent review. 
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In addition to IRIS assessments where chemicals have extensive toxicological 
and/or epidemiological evidence, the US EPA also creates Provisional Peer Reviewed 
Toxicity Values (PPRTV), for chemicals with less data, but toxicity values are still 
required for regulatory purposes. These assessments are similar in scope (hazard 
characterization and dose-response assessment, creation of a provisional RfD or OSF), 
but are frequently an expedited process due to regulatory needs. 
The Centers for Disease Control (CDC) Agency for Toxic Substances and 
Disease Registry (ATSDR) also conducts hazard characterization and dose-response 
assessments to derive Minimal Risk Levels (MRL), which are defined as an estimate of 
the daily human exposure to a hazardous substance that is likely to be without 
appreciable risk of adverse non-cancer health effects over a specified period (ATSDR 
2013). MRLs for acute (≤14 days), intermediate (15–364 days), and/or chronic (≥1 year) 
exposures may be derived, and are frequently used for workplace exposures. 
State-level programs in the US 
The Texas Commission on Environmental Quality (TCEQ) uses a similar 
approach to the Federal EPA IRIS process for derivation of oral and inhalation toxicity 
values (TCEQ 2012). However, the TCEQ has recognized that some dose-response 
relationships may be nonlinear or may have a threshold effect (such as formaldehyde or 
dioxin), and therefore may consider derivation of a toxicity values using mode-of-action 
(MOA) information. Extrapolation is performed to low-dose levels based on that 
chemical's MOA. 
The California Environmental Protection Agency (Cal/EPA) have published their 
own guidelines for derivation of Cancer Potency Factors (Cal/EPA 2009) and Non-
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Cancer Reference Exposure Levels (Cal/EPA 2008). Relative Exposure Levels (RELs) 
are defined similarly to RfD values or concentrations of a chemical at or below which 
adverse non-cancer health effects are not anticipated to occur for specified exposure 
durations. In contrast to the IRIS program, RELs are generated for acute exposure, 
chronic exposure, and eight-hour exposures. The REL methods are similar to the methods 
used for IRIS derivation, with the exception that a BMD default of 5% increase from 
control is used as the benchmark response instead of the US EPA's default of 10%. 
(Cal/EPA 2008). Again, methods for the derivation of cancer potency factors are similar 
to those used at US EPA, with the exception that cancer risk is weighted by a factor of 10 
for exposures that occur from the third trimester of pregnancy to 2 years of age, and a 
factor of 3 for exposures from 2 years of age through 15, regardless to the mode-of-action 
of a chemical, unless chemical-specific data exist to the contrary (Cal/EPA 2009), though 
similar factors have been incorporated in more recent EPA assessments (U. S. EPA 
2005b). 
Internationally 
Since 1969, the International Agency for Research on Cancer (IARC) has 
produced over one-hundred monographs, each containing hazard identification on 
chemicals, mixtures, or other agents may be are carcinogenic, based on human 
epidemiological evidence, animal bioassay evidence, and also mechanistic information 
which is used to strengthen findings found in studies (IARC 2013). Figure 2 presents the 
classification levels for a chemical in an IARC assessment.  
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Figure 2: IARC classification of carcinogenicity, based on human and animal evidence. Note that 
mechanistic data is also evaluated for classification, but is not presented below. Figured adapted from V. 
Cogliano (US EPA) 
 
In contrast to the state or federal process described above, the IARC report does 
not conduct a dose-response assessment or suggest a point-of-departure; classification of 
an agent is the goal. These monographs are designed to be the first step in the carcinogen 
risk assessment, where all relevant information is evaluated to assess the strength of 
evidence that an agent may alter the age-specific incidence in humans. Procedurally, 
there are five groups of individuals that participate in Monograph (IARC 2013): 
1. The Working Group - invited members who have published significant research 
related to the carcinogenicity of the agents in review 
2. Invited Specialists - experts in the field but have a real or apparent conflict-of-
interest 
3. Representatives of national and international health agencies - do not 
participate, but attend due to interest from respective health agencies 
4. Knowledgeable observers - may be admitted in a limited number, to observe 
the meeting but should not attempt to influence it 
5. IARC Secretariat - scientists with relevant expertise who participate in all 
discussions, including the preparation of text, tables, or analysis 
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Preliminary literature searches and working papers are developed by the IARC 
staff, contractors, and the working-group meeting participants in advance of the meeting. 
Then, the working group meets at IARC for approximately a week to formulate a 
conclusion and finalize the texts for these evaluations. For the first few days, subgroups 
in four areas (exposure, cancer in humans, cancer in experimental animals, mechanistic 
and other relevant data) draft summaries of data. Then, during the final days, the 
Working Group reviews all drafts and develops a master report, based on a consensus 
evaluation of the data. This is published as a final within six-months after verification of 
all results from the original literature and technical editing (IARC 2013). 
Recommendations for reform 
The EPA IRIS process has been widely criticized for being scientific flawed and 
too slow (Gray and Cohen 2012). The numbers of IRIS assessments which are being 
produced annually are few, with no more than 20 assessments being finalized annually 
since 1995, as shown below in Figure 3. Some assessments, such as those conducted on 
2,3,7,8-tetrachlorodienzo-p-dioxin can take an extremely long period of time to become 
finalized; in this case, it took over 18 years to go from a draft assessment to a final 
assessment (U. S. EPA 2014a). This may threaten public health as people may assume 
that chemicals without an IRIS assessment may be safer than those which do, and also 
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Figure 3: Annual change in IRIS risk assessments completed by U.S. EPA (Gray and Cohen 2012). 
 
 
A recent peer-review of the draft Formaldehyde IRIS assessment by the National 
Academy of Sciences recommended improvements to both the specific assessment, but 
also more general recommendations for improvement of IRIS assessments as a whole 
(National Research Council 2011). First, the panel reported problems with the clarity and 
transparency of the methods applied in the risk assessment, despite an increase in the size 
of the reports being produced. Second, the panel identified numerous inconsistencies and 
lack of methods reporting on study selection, study evaluation, weight of evidence, and 
derivation of study and endpoint selection for the derivation of the proposed reference 
values. The panel made a number of recommendations to improve the clarity of the IRIS 
assessments, including the following key recommendations: 
 Reduce the volume of text to reduce redundancy and inconsistencies 
 Clearly define the methods used for the assessment including criteria for the 
advancement of studies and endpoints for reference-value derivation 
 Standardize evidence tables and data presented in assessment 
 Critical studies should be evaluated uniformly and summarized in tables 
 Study selection rationale for reference value calculations should be articulated 
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 Weight of evidence descriptions should describe determinants for "weight" 
A number of figures in the (National Research Council 2011) report demonstrate 
recommendations for improving the methodology and data presentation. Figure 4 
presents a potential process for identification which articles were included after a 
literature search, along with details on the count and reasons why articles were excluded. 
Figure 4: Article-selection process, documenting literature identified from literature search, and details on 
the number of articles excluded from the analysis and exclusion details (National Research Council 2011). 
 
 
After the literature body has been reviewed, a subset of studies of sufficient 
quality may provide endpoint details which can be used for derivation of a reference 
value. The reviewers of the formaldehyde assessment found the selection process for 
identification of a single RfC endpoint unclear; Figure 5 was a recommended approach 
for documenting which health-effects, studies, and endpoints were evaluated as a possible 
reference values, and a comparison of the candidate reference values which may have 
been derived. 
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   Figure 5: Illustration of a process for identification of RfC (National Research Council 2011). Health 
effects are selected, then individual endpoints from multiple studies are advanced in parallel, with each 
individual effect representing a candidate point of departure and candidate reference values.  A 
visualization presents the impact of selecting different endpoints on the reference concentration. 
 
 
A separate NRC committee also conducted a review of the draft IRIS assessment 
of tetrachloroethylene (National Research Council 2010). As a similar critique, the panel 
"strongly supports the use of ... graphical aids" in support of reference value comparisons 
among multiple candidate endpoints for the point of departure. A second visualization 
documenting how multiple candidate points-of-departure are advanced to candidate 
reference-values, with different uncertainty factors applied to each is shown in Figure 6. 
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Figure 6: Multiple possible points of departures and candidate reference values of neurological effects of 
tetrachloroethylene; endpoints the committee believed may be most application for RfC derivation are 
shown in bold (National Research Council 2010) 
 
 
Further, many finalized IRIS assessments do not have detailed information for 
reference value-derivation online. Of the 557 substances currently listed on the IRIS 
website (as of March 10, 2014), only 93 (16.7%) had a toxicology review support 
document available for download (U. S. EPA 2014b). Without an extensive toxicology 
review support document, those interested in the derivation of reference values are 
limited to the IRIS summary documentation available on the website. These summaries 
are limited and generally do not provide details on the literature search strategy, inclusion 
or exclusion of candidate studies, or information for why a particular critical effect was 
selected.  
EPA has responded to these critiques and recent IRIS reviews have included a 
preamble detailing how the process is being updated (U. S. EPA 2013b). Attempts to 
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"automate" several parts of the IRIS process have also been mentioned by current 
EPA/NCEA director Kenneth Olden (Jacobs JP 2012). 
Literature search 
In addition to the recommendations made by the NRC for improvement of the 
human health assessment of chemicals, other approaches have been published which 
align well with these recommendations. An approach that applies a systematic search, 
identification, and presentation of studies for inclusion or exclusion from incorporation in 
a study were identified in (Kushman et al. 2013). The approach begins with clearly 
defining the research question, and defining the exact search-strings used by iteratively 
including MeSH subheadings using the PubMed database. After a final search string is 
created, the search was executed, with data and time documented. Tiered inclusion-
exclusion criteria were developed for selecting a subset of literature for inclusion in 
evidence tables, using criteria informed from EPA Cancer guidelines (U. S. EPA 2005a) 
and expert judgment. Figure 7 shows a summary of the process for one possible 
mechanism. 
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   Figure 7: Literature search results of PPARα mechanistic evidence for DEHP (Kushman et al. 2013). 
 
Systematic review 
Scientific evidence in the human-health assessment of chemicals process can be 
used for determination if chemical exposure causes adverse-health effects, or for deriving 
a specific dose corresponding to an adverse effect. The evidence used for the basis of 
these decisions are of variable quality and may come from multiple evidence streams 
such as epidemiological case-control studies, prospective studies, animal bioassay 
information, or mechanistic data. Systematic evaluation of evidence using a defined 
methodology has been applied in the clinical setting for medical interventions using the  
GRADE methodology (Guyatt et al. 2008). However, these guidelines were designed for 
clinical data, not for the diverse data-streams frequently found in environmental-health 
questions. Thus, various approaches have attempted to apply these methods to 
environmental health data, such as the Navigation Guide (Woodruff and Sutton 2011), 
and this approach among others were evaluated for animal bioassay data (Krauth et al. 
2013). 
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One approach developed at the National Toxicology Program (National 
Toxicology Program 2013a) to apply systematic review in hazard identification is 
currently being applied to evaluate evidence for association between Bisphenol A (BPA) 
exposure and obesity (National Toxicology Program 2013b). Each health-outcome is 
individually evaluated, and based on study-design features for studies which evaluate this 
relationship (for example human-controlled-exposure is given a higher-confidence than a 
human prospective study), assigns an initial strength of associations score to that effect. 
Next, studies which contain evidence for these effects are assessed for risk-of-bias, using 
fourteen risk-of-bias questions. Based on the risk-of bias identified for individual studies, 
the overall strength of evidence may be adjusted for the body of evidence in a health 
outcome. The strength of evidence may also be adjusted for other factors, such as 
inconsistency or large variability in the direction or observation of effect. Evidence is 
assessed separately for human, experimental, and in-vitro data. Finally, the adjusted-
strength of evidence for an outcome can be translated into evidence for health-outcome 
conclusions for evidence of effect. 
Utilizing high-throughput screening data 
Recent publications have recommended methods and approaches to transform the 
outdated, inefficient, costly, and animal-centric risk-assessment process to one that is 
more relevant to human health by utilizing 21
st
 century advances in toxicity testing such 
as high-throughput in vitro screening data (Thomas et al. 2013). This includes approaches 
for the conversion of in vitro doses to in vivo estimates using the in vitro to in vivo 
extrapolation (IVIVE), which have the potential to be used to support point-of-departure 
values in assessments. Assays may be identified for genotoxicity, and selectivity 
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(bioactivity), and the most sensitive in vitro results may be converted to an in vivo 
estimation using a hepatic metabolic clearance assays. These screening data can be used 
for prioritization of future of analysis to those which have a smaller margin of exposure 
(MOE) to estimated human exposures. 
Judson et al. 2011 reported on the utilization of high throughput screening (HTS) 
data to estimate a biological pathway altering dose, which could be used for High 
Throughput Risk Analysis. A key assumption made here is a biological pathway modeled 
in an in vitro assay may be linked to an adverse effect -  in some cases this may be direct 
(cholinesterase inhibition), but this is frequently not the case and therefore requires 
justification of a valid mode-of-action for a given assay or collection of assays. While 
still under development, as additional toxicity pathway assays are being developed, this 
approach may be used for developing a tiered testing approach for animal bioassays and 
conventional assessments. 
Crump et al. 2010 has noted on the difficulties of using in vitro assay data and 
toxicity pathways for the development of quantitative risk assessments. Specifically, it 
was noted that extrapolation from simplified in vitro systems to in vivo systems would be 
difficult, and deriving models of such mechanisms may yield high levels of statistical 
uncertainty. Further, intracellular signaling pathways and developmental effects may not 
be captured by current in vitro models. The authors concluded that conceptually, 
approaches used for BMD and NOAEL to POD derivations may be applied to in vitro 
data, but acknowledged there would be far more uncertainty and variability in toxicity 
pathways to account for with this relationships, which may prove difficult to integrate 
into the current risk assessment paradigm and regulatory framework. 
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As an attempt to utilize new data being generated, a prototypical implementation 
of a risk assessment conducted with using HTS data has recently been completed (U. S. 
EPA 2013c). A tiered approach was utilized where HTS screening data was used for Tier 
1 prioritization (incorporation of QSAR and HTS assays), followed by Tier 2 limited-
scope assessments (knowledge mining and short-term bioassay), and finally a more 
traditional assessment with extensive in vivo animal studies and epidemiological data in 
Tier 3.  
Gray and Cohen 2012 recommended expanding the sources of information used 
in IRIS including short-term toxicity studies, and exploration of utilizing the high-
throughput screen data. They recommend not shying away from presenting additional 
data, and possibly multiple risk-values, in order to better acknowledge underlying 
uncertainties which cannot be resolved scientifically.  
Existing software solutions 
There are many publically available databases which contain data frequently used 
in the human health assessment of chemicals, as well as software tools which can assist 
the user in performing a portion of the analysis. The EPA Health and Environmental 
Research Online database (HERO) contains citation information and in some cases full-
text documents for key studies used in EPA risk assessments (U. S. EPA 2014c), and may 
also include tags applied to the literature for a given project (Kushman et al. 2013).  
Multiple publically-available databases contain animal bioassay data which may 
be used in human-health assessments of chemicals. The NTP Chemical Effects in 
Biological Systems (CEBS) database contains all bioassay data, including microarray, 
histopathology, immunology, and clinical test results and observations for over 9,000 
Chapter 1: Literature Review 
20 
individual studies from the National Toxicology Program. (National Toxicology Program 
2014; Waters et al. 2003). The ToxRefDB (Martin et al. 2009) includes thousands of 
studies, complete with NOAEL and LOAEL information for effects based on registrant-
submitted toxicity studies from the US EPA. Controlled vocabularies for effect 
descriptions were also created and utilized in the database. The publically available 
RepDose (Bitsch et al. 2006) database is maintained by the German company Fraunhofer, 
and includes basic toxicological information for 650 chemicals include, study quality 
information adapted from the Klimisch score (Klimisch et al. 1997), doses measured, and 
LOAEL/NOAEL associated with organ and a predefined list of effects. 
Many assessments also utilize mechanistic and in vitro data for supporting 
evidence of association and causation. Mechanistic and in vitro data are also collected in 
large databases, such as the Comparative Toxicogenomics Database (CTD), which 
contains annotated associations of genes, proteins, study references, and toxic agents 
across a range of diverse species for comparative association studies (Mattingly et al. 
2003). The ToxCast database contains dose-response data on 1,800 chemicals and 800 
high-throughput screening assays is also available on the EPA website (U. S. EPA 
2014d).  
For systematic review and data-extraction, software such as DistillerSR can be 
used for data extraction, including defining fields and performing quality-control and 
quality-assessment of data extraction (Stefanison I 2005). However, the software is not 
free, it does not allow for public review of the data, and fields are non-standardized to 
allow for cross-chemical comparisons.  
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The DRAGON software, developed by ICF International, is a database which is 
used to extract and contain data used in chemical risk assessments (ICF International 
2014a). The database is capable of storing literature, animal bioassay, epidemiological, 
and in vitro studies. The software is not publically available, nor are outputs or database 
schemas publically available.  




Multiple regulatory agencies on a state, federal, and international level regularly 
conduct human-health assessments of chemicals in order to establish hazard identification 
or to define regulatory values to protect human-health and the environment. While the 
structure and needs of the assessment vary, there is an consistency in the steps applied 
and the type of data used to make environmental health decisions, based upon a the risk 
assessment framework (National Research Council 1983). This involves problem 
formulation, a literature search for identification of relevant data, selection of a subset of 
the literature for review, detailed review and synthesis of the data, and conclusions based 
on qualitative identification of hazard, or quantitative determination of a reference value 
to protect populations. These human-health assessments of chemicals may serve multiple 
purposes. For example, they may be used to synthesis of multiple evidence streams to 
draw conclusions about the potential health effects from exposure to chemical. 
Alternatively, they may be used to help identify research gaps and to better understand 
data-needs for future research. 
Over the thirty years since the original NRC report, numerous advances have been 
made for improvement of the process. Examples include integration of the benchmark 
dose modeling method for determination of a point-of-departure  (Crump 1984), and 
interspecies dose-adjustment using PBPK modeling to account for physiological 
differences between species and populations. More recently, advancements such as 
systematic study-review and study-bias identification for incorporation into weight-of-
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evidence have also been proposed and are currently applied to some assessments 
(National Toxicology Program 2013b). Further, an unprecedented amount of high-
throughput in-vitro screening data is being generated, and multiple approaches have been 
proposed for integration of these datastreams into future chemical-risk assessments 
(Crump et al. 2010; Thomas et al. 2013; Judson et al. 2011). 
At the same time, the current risk-assessment process has slowed, calling for 
numerous recommendations for improving the consistency, transparency, and throughput 
of these assessments (Gray and Cohen 2012; National Research Council 2011, 2010). 
Further, there is a need for risk assessments, as thousands of chemicals currently in use 
have no safe-level or regulatory value (Judson et al. 2011). The methodological 
improvements above are frequently data-driven and highly quantitative, which if 
implemented efficiently in the current framework, may make an even slower process and 
with less transparent results. 
Given this problem, the goal of this project is to create a functional prototype of 
an online content-management system designed to track key data and expert-decisions 
when conducting the human-health assessment of chemicals. The system should not only 
function as a workspace during development of an assessment, but should also be 
effective at presenting a draft or final assessment to the public. It should attempt to 
integrate existing methods in the assessment process, as well as include recent-best-
practices and recommendations for improvement to the current methods applied. 
Through the development of such a system, we hope that the overall quality, 
throughput, and transparency of the human health assessments of chemicals may be 
improved. Storing the data in a database inherently forces consistency of inputs and 
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decisions. Further, design of a content-management system also can help to standardize 
tables, visualizations, and other outputs of the system.  The design of the system itself 
may also force adherence to guidance where possible. Finally, it may also help to 
enhance transparency, as all data may be viewable using the database, including details 
which may generally be presented in a final document. The use of a database for 
capturing study information and data, as well as more standardized tables and 
visualizations, were key recommendations in the NRC 2011 formaldehyde review 
(National Research Council 2011). Finally, by designing a system to capture much of the 
data used in current assessments, it may be helpful for visualization human health 
assessments in the future, such as those which may contain high-throughput screening 
data. Three goals were determined in an effort to evaluation the prototypical system 
designed: 
1. Requirements identification. Identify modules to allow users to perform key 
steps in the risk-assessment process; including data entry, data analysis and 
integration, presentation, and review. Create specific requirements for each 
module as a blueprint for implementation. 
2. Prototype development. Design a relational-database schema and user-
interface for meeting the requirements identified in the first goal.  This should 
include development both for development and final presentation of 
assessments. This may include designing interfaces to coordinate with existing 
software and/or databases. 
3. Evaluation. Present an existing human health assessment to better understand 
the benefits and limitations of the prototypical system.  
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Chapter 3: 
Materials and Methods 
Requirements Development 
The first goal of this analysis was to identify key steps in the human health 
assessment of chemicals, and to develop a list of requirements for capturing the 
information for these steps. The requirements should be generic enough so that they 
could be utilized a number of different agencies, and therefore should not be locked in to 
any specific process. However, it should be able to capture key steps involved in most 
processes, and be constructed modularly so that if a step is omitted by an agency they can 
simply not use that module in the prototype (for example, if systematic review is not 
conducted, it can be skipped and other requirements will work seamlessly). 
The EPA IRIS process was selected as a key reference for requirements 
identification. The IRIS process is similar to many other programs which evaluate the 
human health assessment of chemicals, but it results in the determination of quantitative 
reference value or cancer slope factors, and therefore includes a detailed dose-response 
assessment for derivation of these values. This is one step beyond many other processes, 
which may result in qualitative hazard classification for compound (IARC, NTP, etc.). 
Thus, by using the IRIS process, requirements can provide hazard classification as well 
as reference-value derivation.  
The preamble for the draft Ammonia IRIS was reviewed (U. S. EPA 2013b) to 
identify requirements. This specific assessment was selected as it included an updated 
preamble which addresses the recommendations made from recent prior peer reviews 
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(National Research Council 2011, 2010) of the IRIS process. The preamble was reviewed 
to identify procedures, input data, and key-decisions which may be amenable for storing 
in a database or structured data system. Procedural components include updates to the 
assessment based on peer-review, as well as final presentation to the public. Numerous 
discussions with experts in the field were also used for module identification and 
requirements development. 
In addition to examining the current practices as implemented by the US EPA for 
IRIS assessments, a subset recent literature for improving the risk assessment process 
were also evaluated. Selection of which ideas to implement were based on ease of 
integration into the current framework, along with relevance to meeting 
recommendations for improvements to the IRIS process (National Research Council 
2011). From this, the concept of developing literature inclusion and exclusion were 
included in software requirements based on the methods described in (Kushman et al. 
2013). Further, systematic study reviews were implemented based on the process 
described in (National Toxicology Program 2013a, b). Common software for data 
visualization was also examined for inclusion in the software system (Boyles et al. 2011).  
Finally, ease of integration with existing software-solutions was also used for 
development requirements. This includes examination of publically-available web-
services to other streams of information, including citations and references in PubMed, 
the US EPA HERO database, physicochemical information in Chemspider, and existing 
database exports for bioassay and epidemiological information, such as DRAGON (ICF 
International 2014a).  
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A schematic for key modules and interactions with the website was developed, 
and used as a framework for construction of the prototype website. A graphic presenting 
key modules, interactions, and exports are shown in Figure 8. 
   Figure 8: Summary of modules, exports, and interactions required for implementation of a web 
application for the development for health assessments of chemicals.  
 
Prototype Development Approach and Evaluation 
After development of modules and requirements to create a content management 
system, a prototypical software implementation would be designed. Given the resources 
available for development and scale of what was to be designed, it was determined that a 
formal software engineering process such as the Waterfall system would likely be too 
burdensome and would not allow for the rapid changes that would be needed to meet the 
requirements. Therefore, a prototype-development process was adopted instead, as shown 
below in Figure 9. This rapid-development process allow for more exploratory 
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development, as well as the ability to refactor or throw-away poorly-performing 
prototypes (Sommerville 2007).  
   Figure 9: Prototypical software development model. Main goals included development of a prototypical 
system to meet functional requirements for creating and displaying data for each module. Efficiency and 
consistent implementation throughout the application were not a performance measures evaluated in 
development of these prototypes. (Sommerville 2007). 
 
 
After prototypical modules were developed, prototypes would be compared to the 
list of software requirements, to determine if requirements were achieved. Requirement 
achievement for the prototypical module was described using the scale shown below: 
1. A “Fully implemented” requirement means that a fully-functional example of 
the requirement is implemented at least once in the prototype; it may not be 
implemented consistently throughout the entire prototype.  
2. A “Partially implemented” requirement means that some aspects of the 
requirement have been completed, but not completely. 
3. “Not implemented” means no aspect of the requirement is functioning in the 
current prototype. 
Software Platform Selection 
A key design decision was made early in the development to create a web-based 
application instead of a standalone application. First, use of a web-application allows for 
multiple users to work simultaneously on one assessment, as human health assessments 
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of chemicals are generally conducted by large teams of experts and supporting 
contractors. Second, use of a web-application allows for scalability and portability. By 
using a web-browser as the primary interface for the application, usability in multiple 
environments is guaranteed, so long as a user can utilize a supported browser. Finally, 
versions can more easily be controlled as only the server requires updating.   
A summary of the system-architecture is presented in Figure 10. The website was 
named the Health Assessment Workspace Collaborative, or HAWC, and is publically 
available at https://hawcproject.org. A number of third-party software packages were 
used in order to develop the website. Software was selected which had a permissive 
open-source license which allows for use and redistribution on open-source projects. 
Further, software was also selected which had sufficient documentation and a large 
number of users, as a proven track record for stability.  
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Figure 10: HAWC website architecture including server, client, and external libraries and databases used. 
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Server libraries 
Python was used as the primary server-side programming language. Version 2.7.3 
was used in development and production, as most third-party packages are compatible 
with this version of the programming language. The Python-based Django website 
framework (version 1.5.5) was selected as the fundamental software framework for the 
website application. It was selected for multiple reasons. First, it is a low-level 
framework which allows for easy customization of database schema, form creation, and 
caching. This in contrast to other frameworks which can do more automatically, but only 
allow for limited customization, as it was expected that a large amount of customization 
would be required. Django is also well established and widely used in the large scale 
production environments, such as NASA, Instagram, and Pinterest (Django Software 
Foundation 2014). Further, it was selected due to the object-relational-model framework, 
where database tables are constructed based on a functional model of an object, which 
should allow for easier model-based development. Finally, it is programmed in the 
Python programming language (Python Software Foundation 2014), a well-established 
language with a solid foundation in scientific programming (Oliphant 2007). 
A number software packages were also used in addition to Django for 
development. South (version 0.7.6) was used for the database migrations, as the schema 
was updated. Django-reversion (version 1.8.0) was used for storing versions of the same 
object after edits were made. Django-rest-framework (version 2.3.12) was used to 
provide a JSON API for data import and extraction. Django-treebeard (version 2.0b1) 
was used for representing hierarchical data in a relational database, using a modified path 
tree traversal (MPTT) database pattern. Django-selectable (version 0.8.0) was used for 
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instant search capabilities for fields with large many-to-many relationships. The requests 
library (version 1.2.3) was used for interfacing with external application programming 
interfaces (APIs) such as PubMed, HERO, or Chemspider. The lxml library (version 
3.0.2) was used for processing XML-based imports from external APIs. To read and 
write Excel files, the xlrd (version 0.9.2) and xlwt (version0.7.5) packages were used, 
respectively. Powerpoint-files were constructed using the python-pptx library (version 
0.2.6). Word files were created using the python docx library (version 0.0.2). 
The Inkscape software package (Inkscape 0.47 r22583) was used to convert 
scalable vector graphics (SVG) rendered on the web-browser to rasterized PNG images, 
as well as PDF files. Inkscape was selected in contrast to more lightweight solutions such 
as ImageMagick as Inkscape has the ability to render SVG files including external 
stylesheets (CSS), which were used widely in the browser for client-side representation 
of the visualizations. 
The memcached software package (version 1.4.5) was used for in-memory 
caching of objects which were computationally-expensive to generate. The Celery 
software package (version 3.1.7) coupled with a Redis datastore (version 2.8.3) was used 
for asynchronous response, such as downloading data from external APIs. 
Benchmark dose modeling software 
BMDS source code from versions 2.20 and 2.40 were both compiled for use the 
HAWC webserver. The software required recompilation as available binaries were only 
available for the Windows operating-system environment, and Linux-based environment 
was used for the server. The gcc compiler (version 4.1.2 20080704) was used to compile 
C and Fortran code. Makefiles were modified slightly with assistance from staff at EPA 
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(Setzer 2012), and modified source code is available 
(https://bitbucket.org/shapiromatron/bmds).  Outputs from the recompiled files were 
modified to note that results are from a custom build-version of the software. Table 1 
presents an overview of BMDS models which were compiled for HAWC. The models 
include those most-frequently used models in the IRIS assessment, however the 
Dichotomous-Hill model was not included because current BMDS documentation does 
not provide details on input-file requirements (U. S. EPA 2012a). 
Table 1:  Model-forms used in BMDS software for continuous and dichotomous datasets 
Dichotomous Models 
Model Name Functional Form 
Required 
Dose-Groups 
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Simple; no background 
Probit  (    ) 2 Simple; no background 
Log-logistic 
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3 All purpose; S-shape with 
plateau at 100% 
Log-probit 
  (   ) {     ( )} 3 All purpose; plateau S-shape 
with plateau at 100% 
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Weibull   (   )      {    }   3 ”Hockey stick” shape 
Continuous models 
Polynomial 
            
        
  1+n All purpose, can fit non-
symmetrical S-shaped 
datasets with plateaus 
Linear 
        2 Linear (subset of 
Polynomial) 
Power       3 L-shaped 
Hill   
    
     
 
4 Symmetrical, sigmoidal,   
S-shape with plateau 
Exponential model family All purpose and plateau 
- Model 2      {    }  2 
- Model 3       {  (  ) }  3 
- Model 4      (   )     {  (  )}  3 
- Model 4      (   )     {  (  ) }  4 
a
 Dose groups required to calculate a mean goodness of fit p-value value assuming all parameters are used 
b 
Model with a few additional restrictions is used to model dichotomous-cancer data 
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For testing of successful compilation, a test-suite provided by developers at the 
US EPA was provided (Gift 2012).   
Database 
The PostgreSQL (version 8.4.20) relational database was used as a database 
backend for the web application. PostgreSQL was selected based on it being the 
recommended database for Django development. A traditional Structured Query 
Language (SQL) database was used in contrast to alternative implementations such as a 
document-based database or node-based. This is because we wished to standardize the 
process, and also allow for predefined interactions and visualizations of the data, which 
requires a consistent structure. One limitation of SQL databases is the rigidity of the 
schema; however it was a constraint was considered useful in our attempt to standardize 
the human-health assessment process. 
The database-design was constructed using a data-driven approach, where the 
database was designed primarily to capture the models and relationships, as opposed to a 
process-driven design where the database was modeled to capture processes (Simsion 
G.G. 2005). While this may not be optimal in terms of efficiency, it is a preferred method 
for capturing the data themselves, which should promote re-usability of data instead of 
design for a particular process which may be more likely to change. 
In most cases, the schema was designed to achieve 3
rd
 normal form 
(Ramakrishnan R 2003) where possible, consistent database design best-practices. In 
doing so, some logical objects such as dose-response endpoint may be expensive to 
generate, as a typical query may require multiple joins to return the required information. 
Therefore, database denormalization and caching were utilized for saving in-memory 
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retrieval of an expensive object. In doing so, an pre-computed object can be retrieved in 
O(1) time by accessing a hash-table stored in memcached.  In a few special cases, objects 
were not stored in 3
rd
 normal form, such as BMD settings, as this would require large 
complicated tables and queries, and it is unlikely that a use-case would require a subset of 
the data. Therefore, these data were stored in Javascript object notation (JSON) format in 
a text-field. 
Client-side requirements and libraries 
A desktop-browser was the primary form of interaction expected to occur with the 
website (not mobile or tablet). Some Javascript libraries require a recent browser, 
therefore a decision was made to restrict use to recent browsers. The recommended 
browser, based on development experience, was decided to be Google Chrome. 
Additional supported browsers include Internet Explorer ≥9, Mozilla Firefox and Apple 
Safari.  
The Django template allows for server-side rendering of database objects. Server-
side rendering can be easy to implement, but it allows for less flexibility and interactivity 
of views. Django templates were therefore used for static displays of data which are 
general displayed on one view (for example, assessment-level options or user login 
information). For database objects which may need to be rendered on multiple difference 
views in multiple contexts (for example, a measured animal bioassay endpoint), a 
Javascript model of the object was created, with the Django server passing the object in 
JSON representation. 
The jQuery software library (version 1.9.0) was render the Javascript object to the 
document object model (DOM), thus rendering a viewable object. In some cases, datasets 
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were retrieved from the webserver using AJAX jQuery libraries. The d3.js library 
(version 3.4.2) was used for SVG generation as it allows for dynamic rendering of SVG 
graphics in modern browsers (Bostock et al. 2011). Many of the figures used for human 
health assessments of chemicals are specialized plots which are not built-in to existing 
graphics packages. Therefore, using a visualization framework, rather than a predefined 
set of plots was an important design consideration. The D3 library was modified slightly 
to use only CSS styles which can be properly rendered in Inkscape for conversion (i.e. 
removal of “em” distances in favor of “px”), with changes available in the source-code 
repositories. 
For popup boxes, the jQuery UI library (version 1.10.0) was used. For general 
website formatting and styling, the Bootstrap package was used (version 2.2.2). This was 
selected for ease-of-implementation, as well as using current best-practices in responsive 
web-design, where resizing is conducted automatically and therefore website views are 
amenable to various screen sizes such as tablets or mobile devices (this was not a key 
design-consideration, but rather an added advantage of using this particular framework). 
The spectrum.js library (version 1.1.1) was used for color-selection. The wysihtml5 
library (version 0.3.0) was used for rich-text editing. 
Website Hosting 
For testing and prototype development purposes, we chose to deploy the software 
using the Webfaction website-host. This platform was selected during development due 
to flexibility, including the ability to compile source-code on the server (which was 
needed for BMDS implementation), as well as reasonable cost and performance. The 
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platform selected was a 32-bit Linux-based CentOS server (version 5.10); selected in-part 
to reduce differences in the environment for BMDS compilation. 
The hosting-platform used is a shared service; multiple users may independently 
access the server and host their websites simultaneously using different ports. Care is 
taken by administrators that unauthorized access by other users is prevented, but being 
that it is a shared server, allows for increased potential for unauthorized access. Given 
that this is a prototypical software system, the potential for unauthorized access is 
tolerable, however, for use in a production environment, it may be advantageous to have 
to deploy in a more secure platform.  Given this, all decision decisions above and 
software decisions were made to allow for easy portability to other platforms, should a 
more secure environment be desired. The only key requirement is a Linux-based server. 
Source-code version control 
Development was completed using the SublimeText2 text-editor (version 2.0.2), 
and tested primarily using the Google Chrome browser (version varies as is updated 
frequently, latest version 34.0).  
All source-code was tracked using the Git software version control system. The 
Git software system incrementally tracks changes to source code incrementally, 
whenever a "commit" is executed, a current list of differences (diffs) are stored using a 
hashed-binary structure internally in the Git software. One advantage of using the Git 
version control system over other version control systems is the fact that all repositories 
are self-contained, and therefore completely distributed. Therefore, a duplicate version of 
the Git repository was stored online using the Atlassian Bitbucket application. Given this, 
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a backup of all source-code and previous versions were always available for disaster 
recovery. 
For deployment, an additional git repository clone was created on the server, and 
when a git-push is received, an automated set of scripts automatically update all source 
code, restart required services, preform database migrations, and reload the website 
application. This allows for rapid prototypical development as required when using the 
prototype software development method. 
Testing 
To ensure that critical functionality performs as expected, unit-testing was 
implemented using the Django unit-testing framework. Critical functionality included 
user-permissions and authorization for viewing and changing content, as this is critical to 
the functionality of the system. However, because this is a prototypical software 
development project, unit-testing was not exhaustive. The rapid pace of change coupled 
with the small development team means that feature creation and core-functionality 
superseded extensive testing. This is consistent with the prototype software engineering 
development process described above. 
Exports, views, and visualizations created were primarily tested using the Google 
Chrome web-browser, with occasional testing in Internet Explorer 11 and Firefox. In 
addition to testing before deploying, automated error-reporting was employed on the 
server. Whenever a server error occurred, it was fixed as fast as possibly, or added to an 
error-list.  
One other key area of testing was comparative testing of BMDS modeling 
software after recompilation for the Linux environment. A test-suite of 100 continuous 
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datasets and dichotomous datasets were provided by the EPA development team; these 
dose-response datasets were run with all dose-response models using model defaults. The 
resulting BMD, BMDL, and AIC estimates were compared from runs in both 
environments. 
Prototypical Chemical Evaluation 
Two different assessments were used for evaluation of the prototypical software 
system. 
First, a finalized assessment was used to evaluate how HAWC web-application 
could display the results from a completed assessment.  The Nitrofen (CAS: 1836-75-5) 
Peer-Reviewed Provisional Toxicity Value (PPRTV) assessment was selected for 
evaluation (U. S. EPA 2012b). This assessment was completed in 2012 by the US 
EPA/NCEA, the same division which produces the IRIS assessments. A PPRTV is 
similar is scope to an IRIS assessment, except it is used to evaluate chemicals with 
limited information, and results in a "provisional toxicity value", in contrast to "toxicity 
values" produced by IRIS assessment. The Nitrofen was selected by NCEA staff as a 
good test-case for the HAWC website, due to its robust database of animal bioassay data. 
The focus for data extraction and import was the non-cancer reference value derived for 
Nitrofen; limited data for cancer potency was extracted for this comparison.  
Second, the prototypical website was also evaluated using an ongoing assessment 
in contrast to a finalized assessment. The ongoing project selected was the National 
Toxicology Program's assessment on the association of Bisphenol A and obesity 
(National Toxicology Program 2013b), again, graciously provided by the study authors. 
There are many differences between this and the previously described Nitrofen 
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assessment. First, this assessment does not include quantitative reference value 
derivation, but instead reports hazard identification and characterization. Next, much of 
the evidence is epidemiological, in contrast to the Nitrofen assessment is exclusively 
animal bioassay. Further, existing data export was available, so data import and export 
from the system were also explored. Finally, study-quality and risk-of-bias information is 
also available, a process not applied in the IRIS or PPRTV process. 
These two assessments were used for evaluation of the prototypical HAWC 
website. Evaluation focused primarily on database structure to ensure that key data could 
be captured, presentation and visualization of the assessment, and evaluation that all key 
steps in the process were captured by the application.  They are sufficiently different, 
with one assessment deriving quantitative toxicity values from primarily animal bioassay 
data, and the other estimating confidence for hazard based primarily on epidemiological 
data.  It should be noted that neither assessment contained an extensive in vitro database, 
so this was not a focus for implementation or evaluation of the HAWC prototype website. 




Prototypical Implementation  
The Health Assessment Workspace Collaborative (https://hawcproject.org) 
originally went live on December 20, 2012, but has been updated frequently since the 
original launch.  A permissive software license was also added for the ability for others to 
use the software system and/or modify source code (see Appendix 1: HAWC License). 
As of April 2, 2014, a total of 1,145 Git-commits have been made to the project since 
December 12, 2012. Source code is available online (see Appendix 2: HAWC Source 
Code). A prototype of the web application created was completed, originally posted in 
late December of 2012. Over forty-thousand lines of custom code were created for the 
development of this website; Table 2 describes the total number of files and lines of code 
by programming language.  
Language 













Python Server-side data-processing; database 106 37% 18,336  42% 
JavaScript Dynamic client-side changes of views 25 9% 14,717  34% 
HTML Templates for rendering views 148 52% 9,568  22% 
CSS Visual styles for website and graphics 6 2% 1,264  3% 
Total 
 
285 100% 43,885  100% 
Table 2: Summary of the total number of files and lines of code (including comments) created for HAWC 
prototype development. These values include only code-customized for HAWC implementation; software 
utilized by HAWC not included. Some programming languages where only minor amounts of work were 
done were excluded from this analysis (R, SQL, bash-shell scripting).  
Assessment Module 
The assessment module was defined to be a top-level container for an independent 
assessment of a single chemical or mixture. In conventional risk-assessment terms, a 
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single assessment might be thought of as one final report, documenting the entire process 
and conclusions. It is therefore the fundamental module which may be considered a 
parent-class to all other modules. This module is designed to create an assessment and 
administer the assessment, including permissions assignment. 
Workspace Requirements 
Requirements for the assessment module are described below: 
 Assessments require a tiered-level of access. Many assessments are created by 
federal or state government agencies, and therefore must be reviewed judiciously 
before internal- or public-review. There should be multiple levels of access. First, 
a project manager should be able to create an assessment, and enable/disable 
access to the assessment. They can also make the assessment locked for editing 
(read-only), or public. Team-members cannot change permissions, but are able to 
edit content, if the assessment is editable. Finally, peer-reviewers can view an 
assessment even if not open to the public, but are unable to change content. 
Finally, an administrator level account (superuser) should always have the 
permission to see all assessment information. 
 Data should be able to be imported from other databases into HAWC. In addition, 
additional information may also need to be added manually. For example, a study 
reference may be imported from PubMed, but the type of study (animal bioassay, 
epidemiology, etc.) may also need to be entered by a team-member. Therefore, a 
mechanism for tracking external import should be in place to keep a primary 
reference for data, but also give a HAWC instance to apply additional metadata. 
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 When changes are made to content, these changes should be tracked in the 
database. This should include the text for what changed, who changed it, and 
when it was changed. Versioning should not be publically exposed, but internal 
review teams or peer-reviewers may have access to this information. 
 Assessments are conducted on a single chemical or a family of related 
compounds. Therefore, assessments should be able to include the chemical name, 
CAS number, or some other identifying feature to allow for querying of related 
chemicals or phsyicochemical characteristics. 
 After an assessment is made public, a possible use case might be to query data 
across multiple assessments. For example, on might be interested in finding all 
assessments where obesogen endpoints were studied in human populations, or 
cases where a particular rare tumor-type occurred in rodents.  
 The problem being identified for the purpose of the assessment is clearly 
characterized on the assessment-level. 
Prototypical implementation 
A database schema was constructed presenting key components of an assessment, and is 
presented below in Figure 11. The assessment application includes development of four 
key tables along with intermediate tables (not represented) including many-to-many 
relationships between. The base table is the Assessment table. There are multiple many-
to-many relationships between assessments and users to allow for permissions-checking 
an authorization of access to an assessment. The ExternalImport schema allows for 
data from other databases to store a database type and primary key, in order to cross-
reference the values in HAWC versus the alternative database. The BaseEndpoint table 
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are endpoint information (bioassay, epidemiological, or in-vitro) assigned to a particular 
assessment. The BaseEndpoint table has a one-to-one relationship with other tables in 
other modules (the animal bioassay and epidemiology modules) which track the 
endpoint-specific value. This master-table was kept as an efficient way to query multiple 
datastreams simultaneously to identify relevant endpoints from possibly different study-
types. For example, a possible-use case may be a user wishes to query both human and 
epidemiological data related to lung cancer. Finally, the EffectTag table enables tagging 
an endpoint with a controlled vocabulary of descriptions. An initial list of values was 
provided from EPA staff (Guyton 2013); but additional tags may be added by users.  
Figure 11: HAWC assessment application database schema.  
 
A summary of how the requirements described above align with the HAWC 
prototypical implementation is presented below in Table 3.  
  





Notes on implementation 
Ability to create new assessments 
without administrator intervention 
Fully 
- 
Tiered-levels of permissions 
include project-managers, 
content-managers, and reviewers 
Fully 
- 
Assessments can be viewed by 




Ability to import data from other 
databases 
Fully 
Framework created for database import and 
tracking; at present must be done manually but 
could be adapted in the future for automated 
uploads 
Ability to see changes to 
individual objects 
Fully 
Implemented with use of the django-reversion 
framework. Note that this procedure is time 
consuming and dependent on model changes; 
therefore visualization of changes is limited, but 
could be expanded 
Assessment includes chemical 
identification descriptors 
Partially 
One chemical CAS can optionally be entered for 
an assessment; details cannot be provided for 
mixtures 
Searches or imports possible 
across assessments Partially 
Database was designed so that such a query 
might be possible; not implemented in 
prototype. 
Research question clearly 
documented Not implemented 
No free-text field describing the problem 
formulation for the current assessment 
Table 3: Summary of assessment requirements and implementation in the HAWC prototype.  
 
Evaluation 
The assessment module is a required component of the HAWC website, and 
therefore was applied for all ongoing assessments in HAWC.  An example assessment 
project-page for the Nitrofen assessment in shown-below in Figure 12.  
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Figure 12: Assessment-level login page for HAWC website. Figure on left shows the view with logged-in 
permissions of a team-member, including the “actions” button for changing content. The figure on the 




An example of object-level tracking and versioning is shown in Figure 13.  
Figure 13: Version-tracking example of object level track-changes in HAWC.  The figure below 
documents version changes to an animal bioassay endpoint aggregation (further described in  
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Literature Review Module 
When conducting the human-health assessment of a chemical, a comprehensive 
literature review is conducted to ensure that all evidence is evaluated for the problem 
identified in the problem formula for the assessment. The literature review involves a 
structured search of relevant literature databases (PubMed, Web of Science, etc.), gray 
literature which may not be found in conventional database searches, and manually 
including other sources identified through other means (expert discussions, historical 
assessment documents, etc.). This module is designed to track key steps in the process of 
study selection for inclusion in the human health assessment. 
Workspace Requirements 
Requirements for the literature-review module are described below: 
 A literature search should be able to be created, including the exact search terms 
used. The date the search was conducted and results found should be returned. If a 
search is repeated, differences in results should tracked and viewable in greater 
detail. 
 Literature may alternatively be imported from databases if the primary keys are 
known. 
 Literature may need to be manually added if not available in a database. 
 Multiple searches may return the same reference; literature duplicate resolution 
must be available and automatic completed where possible. 
 Criteria for literature evaluation (inclusion/exclusion criteria) should be able to be 
applied to individual references. Multiple criteria may be applied to one reference. 
Users can add custom text to describe tag application on a reference. 
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 Literature evaluation criteria should assessment-specific, and should be in a 
nested-structure. For example a tag may be “review study” but would be nested 
under “Exclusion” and “Tier 1”.  
 At least two independent reviewers should independently mark studies for 
inclusion or exclusion, compare results, and agree upon a consensus decision. 
Prototypical implementation 
A database schema was constructed for storing data required for literature-review, 
and is presented below in Figure 14. A Reference is stored as an assessment-specific 
literature item. A reference may optionally have multiple Identifiers, which are links 
to the same item in other third-party databases. HAWC currently supports the PubMed 
and EPA HERO databases, but more could be added in the future with minimal change. 
References may also have multiple ReferenceTags, which can be applied to describe 
inclusion or exclusion criteria. ReferenceTags are custom for each assessment, and are 
implemented using a modified path-tree traversal (MPTT) database design pattern, using 
the django-treebeard software package. The MPTT pattern allows for tags to be saved in 
a single database table, and can efficiently return all descendant or ancestor nodes in a 
single query (writes are less-efficient).  
Search objects are created to track individual searches, and refer a to a list of 
Reference(s) returned by the search.  The Search object contains the query used to 
retrieve the objects. It also includes a list of dates the search was executed (in 
PubMedQuery). Finally, a Search object can also be used to maintain a list of imported 
Reference(s). Each assessment also has a mechanism for manual import of a list of 
references (by specifying PubMed or HERO identifiers), and creation of a Reference 
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manually (by specifying author title, abstract, journal, etc.), if a reference is not currently 
available in a HAWC-compatible database. 
Figure 14: HAWC literature-review application database schema.  
 
A summary of how the requirements described above align with the HAWC 
prototypical implementation is presented below in Table 4. 
Requirement Implementation Implementation notes 
Literature search can be executed 
and tracked 
Fully 
Implemented using PubMed only 
Literature may be imported from 
existing databases 
Fully 
Implemented using PubMed or HERO 




Merging of duplicate literature from 
different searches 
Partially 
Automatically implemented for new 
HERO/PubMed searches/imports; no manual 
functionality  
Criteria for inclusion/exclusion 
applied to reference 
Partially 
Tags can be applied; notes for individual 
references not implemented 
Criteria should be nested, creatable, 
and assessment specific 
Fully 
 
Multiple reviews and consensus 
evaluation 
Not implemented 
No multiple review or consensus reporting; 
each reference only evaluated once 
Table 4: Summary of requirements developed for literature-review module and status of implementation 
in HAWC prototype.  
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Evaluation 
The EPA Nitrofen assessment does provide details on the list of databases used to 
search for Nitrofen, and the date-range for which these searches were conducted 
(November 2011). However, it does not document the search terms or criteria used for 
literature inclusion or exclusion of literature retrieved in the assessment. Therefore, we 
were unable to recreate the results presented in the report. Instead, a simple literature 
search was executed for the Nitrofen chemical assessment using the PubMed interface 
developed in HAWC. A total of 437 references were identified as of April 5, 2014. 
Literature inclusion and exclusion criteria were developed based on Kushman et al. 2013 
and a subset of these results were tagged as example visualization. 
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Since the public release of the HAWC website, other users have used utilized the 
literature search module, including conducting literature searches, creation of inclusion 
and exclusion criteria, and the tagging of literature from these searches. Figure 15 below 
demonstrates tabular and visualization views (intended to present in a format similar to 
Kushman et al. 2013, or NRC 2011 Figure 7-3 ) in HAWC created from the tagging of 
over 750 references imported from a PubMed Search. 
Figure 15: Demonstration of browsing the results of a literature search for examination of studies included, 
and excluded, including reasons for inclusion or exclusion. Table-based view shown in insert A, with 
visualization in B. Example taken with permission from an anonymous private assessment. Live public 
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Figure 16 shows a demonstration of how the results from search are tracked, 
including the search-term used, dates a search was executed, and summary statistics on 
the number and count of references found with each search. 
Figure 16: Example of search-term and results being tracked in the HAWC interface. The search-terms 
used in PubMed are identified, along with the total number of references identified from query execution. 
Date-stamps also included for each time the query has been executed, and the change in references found 




The BPA obesity project did include details on the literature searches, but these 
were not imported into the HAWC database. 
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Study Details and Systematic Review Module 
A subset of references from the literature search module is identified to have 
valuable evidence which may be included in the human health assessment. The goal of 
this module is to provide additional information to a reference which is not available 
from importing a citation information from a database. Users add details such as the type 
of study (animal bioassay, epidemiology, etc.), as well an optional study-summary. A 
user may also optionally conduct a risk-of-bias assessment, using key concepts from the 
National Toxicology Program’s systematic review framework (National Toxicology 
Program 2013a). 
Workspace Requirements 
Requirements for the study-detail and systematic-review module are described below: 
 Additional study information, not available in a reference database, can be added 
to a study which is of importance in an assessment.  Examples include funding 
details, conflicts of interest, or summary of relevant findings.  
 For risk-of-bias, study quality domains and metrics may be assessment-specific 
and requirements can be changed. This may also include determining which 
metrics are appropriate for particular study-types (bioassay, epidemiology case-
control, epidemiology prospective, etc.). 
 For each metric, a qualitative score and details justifying this score can be applied 
for each study. 
 Metric-scores may be overridden at the endpoint-level, if risk-of-bias is different 
for a particular health-outcome versus a study overall. 
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 Risk-of-bias comparisons across multiple studies in an assessment can be 
conducted. 
 Study bias for an effect is given a score based on study-design features from 
studies reporting this effect. The score can then be upgraded or downgraded from 
the initial score based on expert judgment, and change is documented. 
 At least two independent reviewers can independently assess a study, compare 
results, and agree upon a consensus decision. 
Prototypical implementation 
A database schema was constructed presenting key components of an assessment, and 
is presented below in Figure 17. A Study is a OneToOne relationship with a Reference, 
which is from the Literature Search module. Additional information can be associated 
with a Study which is not available with a Reference (conflict of interest, risk of bias, 
study summary, study-type selection). Each assessment may have an independent set of 
StudyQualityDomain. These domains are associated with one or more 
StudyQualityMetric, or individual questions with a particular domain. By default the 
domains and metrics used for a new assessment in HAWC are taken from the NTP 
protocol for Bisphenol A (National Toxicology Program 2013b), however domains can 
be changed or removed if an assessment will not include systematic review.  After 
domains and metrics are completed, individual studies can report StudyQuality 
information for each StudyQualityMetric.  
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Possible scores for each metric were set using the framework proposed by NTP 
(National Toxicology Program 2013a): 
 ++ : Definitely low-risk of bias 
 +  : Probably low-risk of bias 
 -  : Probably high risk of bias 
 -- : Definitely high risk of bias 
 N/A: Not applicable 
Figure 17: HAWC study-quality application database schema.  
 
A summary of how the requirements described above align with the HAWC 
prototypical implementation is presented below in Table 5. 
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Requirement Implementation Implementation notes 
Additional study information not 
available with a citation can be stored 
with a Study object 
Fully 
 
Study quality domains and metrics are 
assessment-specific and their 
requirements can be customized 
Partially 
Metrics and domains are fully configurable 
for assessment, but requirements based on 
study-type (bioassay, prospective, case-
control, etc.) cannot be changed 
Qualitative score and details for 




Study-bias for specific endpoint can be 
overridden from study score 
Not 
implemented 
Only implemented on a study-level; not on 
an endpoint-specific level 
Comparisons of risk of bias across 
studies 
Fully 
Two example visualizations are shown 
which contain scores from multiple studies 
Overall effect confidence score is 
calculated and can be adjusted 
Not 
implemented 
No calculation of effect-score is completed; 
only study-level risk-of bias conducted. 
Multiple reviewers can independently 
review and create consensus score 
Not 
implemented  
Table 5: Summary of requirements developed for study-quality module and implementation in HAWC 
prototype.  
Evaluation 
The Nitrofen assessment did not report systematic study quality; therefore values 
from the report could be implemented. However, example study-quality scores are 
presented for the Nitrofen assessment, though the scores and notes detailing justification 
were scores are example-only. 
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The BPA obesogen assessment did extract risk-of-bias information for studies. 
Details for an individual study’s risk of bias are presented below in Figure 20.  
Figure 18: Individual risk of bias assessment for one study. Donut-Plot in insert A is used to demonstrate 
a quick summary of bias for the whole study; users can interactively view details on specific metrics by 
hovering their mouse (plot below shows results for the section highlighted in blue). The summary table 
shown in insert B is details all results in a tabular format, organized by Domain. Examples shown below 
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One core purpose of systematic review is to integrate the relative quality of 
multiple studies based on defined criteria in order to draw conclusions about the weight 
of evidence for a given outcome. Example visualizations in HAWC which demonstrate 
integration of results by metric across multiple studies are shown in Figure 19. The 
heatmap example (insert A) was created to recreate Table 4 in National Toxicology 
Program 2013a; the stacked-bar chart example (insert B) was intended to recreate Table 
11 in National Toxicology Program 2013a. 
Figure 19: Examples from BPA assessment demonstrating integration of study bias results across 
multiple studies. Insert A shows each metric as a row, and each individual study as a column; the 
qualitative score for each is shown. Note the plot is interactive; clicking on any row, column or cell will 
show the details for the qualitative score. Insert B demonstrates is a stacked-bar plot showing the fraction 
of studies evaluated, weighted by the number of studies reporting a given score. Heatmap (Nitrofen). 
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Animal Bioassay Module 
One datastream widely used in the human health assessment of chemicals are 
controlled animal exposure studies, or animal bioassay studies. The animal bioassay 
module is intended to contain quantitative data frequently used in these assessments. 
Workspace Requirements 
Requirements for the animal bioassay module are described below: 
 Extract and store experimental information including duration of study, 
species/strain/sex, and generational relationships for reproductive studies. 
 Extract and store group-level dose-response data including mean, standard 
deviation, standard error, incidence, etc. 
 Extract and store individual animal response data (if available). 
 Allow for doses to be represented using multiple dose-units, to allow for PBPK, 
dosimetry conversions, etc. 
 Repeated response measurements over multiple times should be stored in software 
with relationships preserved. 
 Endpoint tags and controlled vocabulary can be applied to endpoints, to tag 
system of effect, effect-type, etc. Tag-structure should be hierarchical, and 
possibly ontology-based to allow for semantic search.  Multiple tags should be 
able to be applied to a single endpoint. 
 Search for endpoints using tags or other identifying characteristics. 
 Simple statistics can be calculated for trend or dose-group significance if statistics 
were not reported, or to use more current statistical methods (Welch’s t-test, 
Fischer Exact Test, Peto Test, Cochran-Armitage Trend-test, etc.) 
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 Collections of related endpoints can be created as defined by the user. Custom 
text can be added to describe this collection. 
 Candidate uncertainty factors can be added to collections of endpoints. 
Uncertainty factors can also be applied and reference values can be created. 
 Batch upload or import multiple datasets; accessible via a user-interface. 
 Tabular and report-based exports should be available. 
 Independent reviewers can extract animal bioassay assay information, compare 
results, and agree a consensus, QA/QC result. 
Prototypical implementation 
A total of 16 main tables (not including many-to-many intermediate tables) were 
created, and presented below in Figure 20. The basic hierarchy for data storage is as 
follows. A Study may have multiple Experiment(s). Each Experiment may have 
multiple AnimalGroup(s), which are sets of related animals which may be compared (for 
example, Male F344 rats). Each AnimalGroup will have a DosingRegime and a collection 
of individual DoseGroups. In addition, each AnimalGroup may have multiple 
Endpoint(s), and each Endpoint will have one EndpointGroup for each DoseGroup of 
the same AnimalGroup. If individual animal data are available, each animal will be an 
IndividualAnimal which is related to one EndpointGroup. The Species and Strain of 
animals are stored in additional tables to force controlled-vocabulary for these items. 
An Aggregation can be created for users to create a custom collection of 
Endpoint objects. Custom text can be added to describe an Aggregation. It is also 
possible to add a set of UncertaintyFactor values (value and description for 
justification) to each Endpoint in an Aggregation. Alternatively, a ReferenceValue 
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can be created in which a single point-of-departure is identified, and a set of 
UncertaintyFactor values can be applied, and the result is a final reference-value.  
Data in the Animal Bioassay module is assessment-specific, with the exception of the 
following fields: 
 Species and Strain 
 DoseUnits 
 EndpointTags (labels which can be applied to an Endpoint) 
Note that types of uncertainty values which can be applied are hard-coded, and 
consistent with the EPA IRIS process. Available uncertainty-values include: 
 UFA: interspecies uncertainty factor. 
 UFH: intraspecies variability factor. 
 UFS: Subchronic-to-chronic extrapolation. 
 UFL: Use of A LOAEL in absence of a NOAEL.  
 UFD: Database incomplete.  
 UFD: Other.  
By default all uncertainty values are equal to 1. 
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Figure 20: HAWC animal bioassay application database schema.  
 
A summary of how the requirements described above align with the HAWC 
prototypical implementation is presented below in Table 6. 
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Requirement Implementation Implementation notes 
Extract experimental-details on an 
animal bioassay 
Fully  
Extract dose-response summary-data 
for a measured effect 
Partially Fully implemented; standard-errors cannot 
be captured (must be converted to 
standard-deviations) 
Extract individual animal data Fully  
Extract repeated-response 
measurements over time 
Partially Can be stored as independent endpoints; 
relatedness not preserved in database 
Allow multiple dose-units to be 
assigned to the same experiment 
Fully  
Controlled vocabulary for endpoint 
tagging 
Partially Vocabulary is controlled, can be added, 
but is not hierarchical, ontological, or 
semantic 
Custom searches of endpoints via tags 
or other fields 
Fully  
Simple dose-response dataset statistics 
can be calculated for significant groups 
or trend-tests 
Not implemented  
Create custom collections of endpoints Fully  
Apply uncertainty factors to custom 
collections or single endpoints 
Fully  
Batch-upload multiple endpoints Partially Completed offline but currently no method 
exists for user to upload custom file 
without administrator intervention 
Tabular- or report- views can be created 
from animal bioassay information 
Fully  
Independent reviews can extract data 
and QA/QC 
Not implemented No QA/QC functionality currently in 
HAWC 
Table 6: Summary of requirements developed for animal bioassay module and implementation in the 
HAWC prototype. 
Evaluation 
The EPA Nitrofen PPRTV assessment contained an extensive amount of animal 
bioassay information, and the point-of-departure which was derived from a 
developmental rat study. Therefore, key dose-response data discussed Nitrofen 
assessment documentation were extracted and added to the HAWC database. Data-entry 
was relatively quick, since the data were already precompiled in the final Nitrofen 
assessment (<16 hours). Figure 21 presents multiple website views describing how data 
are captured form the experiment to endpoint-level using the animal bioassay module. 
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Figure 21: Sample animal bioassay data sample extracted from Nitrofen assessment and visualized in 
HAWC. Insert A presents an experiment including bioassay study-type, chemical purity, and a textual 
summary of the methods for the experiment. Insert B documents details on a specific Animal Group, or 
comparable set of animals. Note that multiple dose-values can be provided for the sharing dosing regime, 
to allow for conversion or incorporation of estimated internal dose concentrations from a PBPK model. 
Insert C presents details on an endpoint measured in animal-group, including study summary data and 
visualization of the raw data in both scatterplot and bar-chart form. Finally, insert D presents individual 










NRC recommends presentation of other potential reference values, and the impact 
of their selection of the final point-of-departure. Because the Nitrofen assessment did not 
present this information, a sample of other endpoints in the assessment were selected for 
presentation below. Figure 22 below presents a user-defined collection of endpoints 
which may be considered candidates for a point of departure.  These endpoints are 
displayed in traditional comparative views (exposure-response array and forest-plot), as 
well as with candidate uncertainty factors applied (intended to recreate National Research 
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Figure 22: Endpoint aggregation of user-defined collection of related endpoints. Summary text describing 
these endpoints also included in hyperlink. Insert A demonstrates presentation in exposure-response array 
form; Insert B demonstrates presentation using a forest-plot for each individual dose group; Insert C 
presents candidate reference values after application of endpoint-specific uncertainty factors. Insert A and 
B. Insert C.  
 
 
Derivation and documentation of an oral reference value was also completed, 
presenting conclusions from Nitrofen assessment. Figure 23 displays a detailed page 
regarding selection of the oral subchronic reference dose including text for justification, 
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Figure 23: Nitrofen oral RfD presentation on HAWC. Captures point of departure, individual uncertainty 





One Nitrofen data-table which could not be entered into the HAWC software was 
the mean body weights over multiple weeks in a two-year bioassay, presented in table 
B.6 of the original assessment.  The prototype does allow for each time-point to be 
entered, but endpoints are treated independently and the time-relation is lost in the 
prototypical database. Modifying the database schema to allow multiple-response 
endpoint-relations is possible, but was not completed. 
A small amount of animal bioassay information was also available automatically 
imported into HAWC from the BPA obesity project; there were no issues in uploading 
data from the BPA assessment into the prototypical framework.  
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Benchmark Dose Modeling Module 
Benchmark dose-modeling is a commonly used method in risk assessment, and is 
the preferred method for deriving a point-of-departure in the EPA IRIS process if an 
animal bioassay endpoint is used and the data are amenable to modeling. A frequently-
used software modeling suite used is the EPA’s BMDS software. This module was 
included in the HAWC software as a prototypical example of how analysis of an endpoint 
may be able to be included in a content-management system.  Details for implementation 
are documented below. 
Workspace Requirements 
Requirements for the benchmark dose module are described below, much of which is 
based on the BMD guidance (U. S. EPA 2012a): 
 If dose-response data are available in animal bioassay and data are amenable to 
BMD modeling (i.e., all required inputs are available), then it should be available 
for modeling 
 The current version of EPA BMDS software  should be used (version 2.40) 
 Standard BMD models in BMDS used for evaluating continuous, dichotomous, 
and dichotomous cancer datasets should be available. More complex models in 
BMDS for handling customized data types (time-to-tumor, multiple-tumor, 
repeated-response, etc.) will not be included. 
 Recommendation logic should be clearly defined and internally consistent for all 
modeling in an assessment. A user should ultimately select a best-fitting model; it 
should not be selected by a formula or algorithm. 
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 Model-selection of single model and single BMR should be conducted, and users 
should have a text-field to justify their selection. 
 Detailed exports including raw modeling outputs should be available. 
 Web-services should be created to allow users to anonymously run datasets not 
currently included in an assessment on HAWC. 
Prototypical implementation 
A database schema was constructed for storing data required for benchmark dose 
modeling, and is presented below in Figure 24.  A design-decision was made to store all 
modeling inputs and outputs for BMD modeling in a denormalized schema using text-
fields and storing data in JSON notation. This greatly simplifies that database 
implementation, at the expense that any database queries which would involve BMD 
modeling inputs or outputs would require processing of the JSON.  
A BMD_session is associated with a single Endpoint object from the animal 
bioassay module. A session includes a version of the BMDS software, and a list of all 
BMR to be executed for each model. Then, each individual model is saved using a 
BMD_model_run. For example, model-run may be the Power model with at 1 SD BMR, 
while a second model-run may be the Polynomial model with 10% relative-risk BMR. 
All overrides from defaults are saved, along with the graphical output figure, modeling-
output text, and output parsed with each model-run. 
In addition to Endpoint-level outputs for a BMD modeling run, assessment-level 
options are also saved, to ensure consistency in model approach across an assessment. 
The BMD-Assessment_Settings object saves the version of BMDS to be used for all 
modeling in an assessment. Finally, decision logic rules for model recommendations are 
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stored in the LogicField table. Details on model recommendation logic are further 
described below. 
Figure 24: HAWC benchmark dose database schema. 
 
A summary of how the requirements described above align with the HAWC 
prototypical implementation is presented below in Table 7. 
Requirement Implementation Implementation notes 
BMD modeling can be applied to any 
endpoint if data available 
Fully 
 
Modeling uses current version of 
BMDS software 
Partially 
Current version used but required 
recompiling, resulting in different 
numerical results (see details below) 
Standard BMDS modeling 
implementations are available 
Fully 
 








Full-export including original text and 
output figures are available 
Fully 
 
Web-services for running BMDS for 
data not currently in HAWC 
Not 
implemented Not considered major priority 
Table 7: Summary of requirements developed for benchmark dose modeling module and implementation 
in the HAWC prototype. 
BMDS model implementation 
To run BMDS on the webserver, each model was recompiled, as previously 
described in the methods section. To test successful compilation and replication of 
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results, a test suite of 100 continuous input datasets and 100 dichotomous input datasets 
were provided by the BMDS software team (Gift 2012). These 200 datasets were run 
using all standard model options, using the original Windows binary files available on the 
EPA website and the recompiled executables. Differences in BMD, BMDL, and AIC 
values were compared. A summary of differences for dichotomous model results are 
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Table 8: Dichotomous BMD model results using original and re-compiled models 
 
As shown from the table above, for dichotomous models, results were almost 
always identical, with a total of 6 BMD and 1 BMDL resulting in a slightly-different 
result (0.1 units) using the two model versions. AIC values were identical in all cases. A 
few output files were examined for differences in outputs, and large differences were 
found in parameter estimations; however, the overall fit was nearly identical, and a 
maximum BMD difference of 0.001 units was observed.  



















Comparing BMD estimates 




















































































































































































Table 9: Continuous BMD model results using original and re-compiled models 
 
 As shown in the table above, there are many more cases where continuous model 
BMD, BMDL, and AIC estimates are not exactly the same between model versions. In 
particular, more complex models with additional parameters (Exponential M4, 
Exponential M5, and Hill) had a larger number of differences. These results were 
consistent regardless of BMD, BMDL, or AIC metric, indicating that parameter 
estimation for the model was different, resulting in different mean-model fits. In some 
cases (particularly the Hill model), BMDL appeared to be more consistent between 
model versions than the BMD or AIC; this is because BMDL estimation failed in both 
cases, so model-failure was consistent in both cases rather than minor differences. 
To further examine differences found in the continuous model results, all 
continuous models which had a BMD estimate difference greater than 0.1 units between 
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models were examined (54 of 752 models, or 7.2%). Figure 25 below presents the total 
number of cases where complete model failure occurred in the standard (downloadable 
binary BMDS model from EPA website) and the new (recompiled version), and then for 
cases where model failure did not occur, a histogram of percent difference between BMD 
values using the two different models. 
Figure 25: Examination of BMD estimate differences in continous models where BMD estimate between 
“standard” model available on the US EPA website is greater than 0.1 units different from the recompiled 





As shown in the figure above, it does not appear that the recompiled models fail 
more frequently than the original models, since both show two-cases where one model 
failed to estimate a BMD while the other was successful. In the majority of cases where 
the BMD estimation was different, in two-thirds of the cases, the absolute percent 
difference between models was less than 1%. However, some cases do exist where BMD 
model estimates differ by greater than 1%.  
The same source-code was used in either case (with the exception of modifying 
the textual output version), so there are no differences in code which might lead to these 
results. However, the compilation environments were quite different, and different 
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compilers were used. Therefore, it is likely that differences in compilers resulted in 
different binary representations, or differences in third-party libraries gave different 
results. These results are generally not extremely different, but they are different, which 
may be important in a regulatory context. Therefore, utilization of the original source-
files executed in a Windows-emulated environment, or using a second decided Windows-
server to run BMDS runs, may be explored in the future, should numerical difference 
resolution in BMDS estimation be considered a priority. 
Decision and Model Recommendation Logic 
EPA guidance on benchmark dose modeling suggests running a suite of models to 
a single set of dose-response data, and then a single best-fitting model is selected.  
Guidance provides a method for selecting a best-fitting model, generally by selecting the 
model with the lowest AIC to balance model accuracy to fitting the observed data with 
parsimony. However numerous other factors are evaluated to ensure that model selection 
is appropriate, again, much of which is available in current guidance. 
To streamline the model selection process, model-recommendation logic used 
previously in the BMDS Wizard (ICF International 2014b) and standardized BMD 
calculations (Wignall et al. 2014) was implemented into the HAWC prototype. Warnings 
are presented to the user to guide user in selection of a best-fitting model. A best-fitting 
model is also recommended, by binning models of equivalent quality in three bins: 
viable, questionable, or unusable.  Table 10 demonstrates the default model-
recommendation logic used for an assessment, though alternative logic can be changed 
by a user, or removed entirely if desired. 
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Test Description  




if Test is True  





BMD is not calculated  on  on  on  N/A  Unusable  Invalid BMD  
BMDL is not calculated  on  on  on  N/A  Unusable  Invalid BMDL  
BMDU is not calculated  off  off  on  N/A  Viable (warning) Invalid BMDU  
AIC is not calculated  on  on  on  N/A  Unusable  Invalid AIC  
Wrong variance model  off  off  on  0.1 Questionable Wrong variance model (p-test 2 fail)  
Variance modeled poorly  off  off  on  0.1 Questionable Variance modeled poorly (p-test 3 fail)  
Goodness of fit p-test  on  off  on  0.1 Questionable  Goodness of fit p-test < 0.1  
Goodness of fit p-test (cancer)  off  on  off  0.05 Questionable  Goodness of fit p-test < 0.05  
Ratio of BMD/BMDL (serious)  on  on  on  20 Questionable  BMD/BMDL ratio > 20  
Ratio of BMD/BMDL (caution)  on  on  on  5 Viable (warning)  BMD/BMDL ratio > 5  
Abs(Residual of interest) too large  on  on  on  2 Questionable  |Residual of interest| > 2  
Abs(Residual at control) too large  on  on  on  2 Questionable |Residual at control| > 2  
BMDS Model Warnings  on  on  on  N/A  Viable (warning)  BMDS output file included warning  
BMD higher than highest dose  on  on  on  1 Viable (warning)  BMD higher than maximum dose  
BMDL higher than highest dose  on  on  on  1 Questionable  BMDL higher than maximum dose  
BMD lower than lowest dose 
(warning)  
on  on  on  3 Viable (warning)  BMD 3x lower than lowest non-zero dose  
BMDL lower than lowest dose 
(warning)  
on  on  on  3 Viable (warning)  BMDL 3x lower than lowest non-zero dose  
BMD lower than lowest dose 
(serious)  
on  on  on  10 Questionable  BMD 10x lower than lowest non-zero dose  
BMDL lower than lowest dose 
(serious)  
on  on  on  10 Questionable  BMDL 10x lower than lowest non-zero dose  
Poor control dose std. dev. estimate 
off  off  on  1.5 Questionable 
Modeled control response std. dev. >|1.5| actual 
response std. dev.  
Table 10: Default BMD decision logic for model recommendation 
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Evaluation 
The point-of-departure used in the Nitrofen PPRTV assessment for the oral 
reference value was derived from benchmark dose modeling on a developmental 
endpoint. The same endpoint was evaluated in the HAWC interface.  Figure 26 below 
presents the model setup options for the BMDS interface using the diaphragmatic hernias 
dataset from Nitrofen for input data. 
Figure 26: Example modeling setup for subchronic reference value in Nitrofen assessment. Insert A 
presents dose response data for selected dataset, and benchmark dose modeling setup for this endpoint. 
Individual models are shown below the dataset; non-default overrides are shown in the non-default 
settings (all model-options, including default configuration, are shown in insert B). In contrast to the 
standard BMD GUI, the BMR selection is conducted independently of model configuration, so that all 




The calculated BMD and BMDL values which were estimated using the 
recompiled HAWC version of the benchmark dose-software were identical to those 
presented in the Nitrofen assessment. A summary of the results, including model 
recommendation using the customized decision logic and model selection and 
justification for the selection of the best-fitting model are shown below in Figure 27. The 
B 
A 
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BMDL estimate in the recompiled BMD models in HAWC is identical to the value 
presented in the original Nitrofen assessment. 
Figure 27: Recommendations for BMD model selection shown in insert A. Calculated AIC, BMD, and 
BMDL are shown, along with notes describing the status of each BMD logic test evaluated. The color-
coding indicates model recommendation for selection based on the results of the log tests, and the user-
settings for evaluation in the assessment. Insert B presents a graphical display of model fit, including 
model comparison of fit (selected best-fitting model in red; alternative model in blue). Details on the 
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Finally, Figure 28 presents the decision logic used for model recommendations 
throughout the assessment.  
Figure 28: BMD decision logic configuration applied to all BMD model runs for a selected assessment. 
Details on definitions are shown in popup boxes (as is presented in figure). Hyperlink. 
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Epidemiology Module 
Epidemiological-evidence is a second widely-used datastream in the human 
health assessment of chemicals. A wide variety of epidemiological studies are used to 
evaluate the human exposure to environmental toxicants, as case-control studies are 
frequently rare. Therefore, a flexible module for epidemiological data was required. 
Workspace Requirements 
Requirements for the epidemiological data module are described below: 
 Extract key details for study-population demographics and criteria used for 
inclusion or exclusion of individuals from the study-population  
 Extract quantitative values including odds ratios, relative-risks, or population 
mean values for exposure-groups, and include confounders assessed and used in 
final models presented 
 Endpoint tags and controlled vocabulary can be applied to endpoints, to tag 
system of effect, effect-type, etc. Tag-structure should be hierarchical, and 
possibly ontology-based to allow for semantic search.  Multiple tags should be 
able to be applied to a single endpoint. 
 Search for endpoints using tags or other identifying characteristics. 
 Candidate uncertainty factors can be added to collections of endpoints. 
Uncertainty factors can also be applied and reference values can be created. 
 Batch import multiple datasets instead of manual-data entry 
 Tabular and report-based exports should be available 
 Independent reviewers can extract epidemiological information, compare results, 
and agree a consensus, QA/QC result. 
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Prototypical implementation 
A schema was constructed presenting key components of the epidemiology 
module, and is presented below in Figure 29. A total of 9 main tables (not including 
many-to-many intermediate tables) were created. The basic hierarchy for data storage is 
as follows. Each Study may have one or more StudyPopulation(s) which are 
collections of individuals with possible Demographic information associated with the 
population as a whole. In addition, criteria for inclusion and exclusion for the 
StudyPopulation are saved in the StudyCriteria table. These criteria are assessment-
specific controlled vocabulary. Each StudyPopulation may have multiple chemical 
Exposure measurements, such as urine metabolite concentrations or exhaled breath 
concentrations. An Exposure may have multiple ExposureGroup(s), or subpopulations 
of a StudyPopulation which are comparable but have different exposure concentrations 
(as defined by the user, be it quartiles, case-control, etc.). Each ExposureGroup may 
optionally include Demographic information to better describe demographic differences 
from the overall StudyPopulation. In addition, each Exposure may have multiple 
AssessedOutcome(s), or measured phenotypic outcomes. One type of statistic (odds 
ratio, relative risks, means) can be recorded for each ExposureGroup within an 
AssessedOutcome. In addition, multiple Adjustment Factor(s) may be applied to an 
AssessedOutcome for confounders that were included in the final statistics, as well as 
confounders which were considered but not included in the final statistics presented. 
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Figure 29: HAWC epidemiology database schema. 
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A summary of how the requirements described above align with the HAWC 
prototypical implementation is presented below in Table 11. 
Requirement Implementation Implementation notes 
Extract details for study population 
including inclusion/exclusion criteria 
Fully 
 
Extract quantitative data for assessed 




Controlled vocabulary for endpoint 
tagging Partially 
Vocabulary is controlled, but can be 
added, and not hierarchical, ontological, or 
semantic 
Custom searches of endpoints via tags 
or other fields 
Not implemented 
Not implemented at this time, but could be 
added with minimal effort 
Apply uncertainty factors to custom 
collections of assessed outcomes or 
single assessed outcomes 
Not implemented 
Not implemented at this time, but could be 
added with minimal effort 
Batch-upload multiple epidemiological 
data for import into database Partially 
Completed offline but currently no method 
exists for user to upload custom file 
without administrator 
Tabular- or report- views can be created 
for exporting epidemiology information 
Fully 
 
Ability to mark records as QA’d Not implemented No QA/QC functionality in HAWC 
Table 11: Summary of requirements developed for epidemiology module and implementation in the 
HAWC prototype.  
Evaluation 
The Nitrofen PPRTV assessment did not include any human data, and therefore 
the Nitrofen assessment does not contain any epidemiological information. 
However the BPA obesity analysis was composed primarily of epidemiological 
data. Much of the data was originally extracted using the DRAGON software, and then 
exported into an Excel document. An automated procedure was created to import the data 
from Excel to the HAWC website. Representative examples of epidemiological data 
presented in the HAWC website are shown in Figure 30 and Figure 31.  These visuals 
present the hierarchical data structure of the epidemiological data previously described. 
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Figure 30: Cross-sectional study population with exposure and exposure groups defined. Insert A 
presents the entire study-population which was assessed in the Transande et al. 2012 analysis, with 
demographic details on the population. Insert B presents a specific exposure-metric which was measured, 
with details on each the measurement technique and exposures found in each exposure-group quartile. 
 
 
Figure 31: Example of one assessed-outcome evaluated for the study population presented above. 
Diagnostic details for measurement of outcome are reported, along with any adjustments made for odds 
ratios in covariate analysis (insert A). Tabular and forest-plot representation of are presented for each 
exposure group (insert B), along with reported significance from control population (in this example, Q1 
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In Vitro Module 
The in vitro module houses a third type of data which are used to some extent in 
human health assessments currently but is likely to be used to a much greater extend in 
the future. Programs such as the EPA Tox21 program already maintain a database for 
storing High Throughput Datasets (HTS), so coordination between the prototypical 
framework and existing software is critical. These data may include Ames mutagenicity 
assays, receptor-binding affinity assays, or studies which may measure cytotoxicity.  
Because of the complexity of in vitro data and the limited use in current human-health 
assessment of chemical frameworks, requirements were identified but no prototypical 
module was developed in HAWC.  
Workspace Requirements 
Requirements for the in vitro module are determined below: 
 Enable capturing data where all doses are presented and individual responses are 
captured for each plate, or summary data where only a dichotomous 
positive/negative effect or continuous EC50-like value is presented 
 Querying existing databases online to access and/or import relevant datasets 
 Capture all inputs required for IVIVE estimation of dose. This may include 
addition results from other assays, such as hepatic metabolic clearance or plasma-
protein binding (Thomas et al. 2013).  
 If data are available, perform extrapolation and estimation of dose to predicted 
human-equivalent using IVIVE approach 
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 Creation of a pipeline to allow derivation of a point-of-departure from in vitro 
data (using IVIVE extrapolation), and allow enabling or disabling at the 
assessment–level. 
 Provide automated or semi-automated tables for documenting genotoxicity in 
traditional in vitro assays such as Ames mutagenicity assays 
 Provide ability to generate automated reports of user-defined collections of related 
evidence (online, tabular, and document-based). 
Prototypical implementation 
A prototypical implementation for capturing in vitro data was not completed. 
Evaluation 
A prototypical implementation for capturing in vitro data was not completed. 
Data Summary and Visualizations 
Prior modules described in previous sections have focused on capturing the data 
and decisions for components of a human health assessment. Ultimately however, the 
results must be integrated into a report which synthesizes the data which are available, 
and the conclusions which have been made to conclude hazard identification of dose-
response assessment. The data summary module was created for synthesis of data from 
the other modules, as well as to provide a mechanism for peer-review and feedback. 
Workspace Requirements 
Requirements for the summary module are described below: 
 Custom, free-text documentation should be able to be created using rich-text 
formatting and a hierarchical document structure 
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 Integration of data tables and graphics from other modules should be accessible 
via in-text interactive popups to provide further detail.  
 Online reports should be downloadable in Microsoft Word format. 
 Custom visualization for displaying hazard identification classification, including 
details on the underlying data and assumptions used for this classification. This 
may be similar to a table for carcinogenicity classification  (IARC 2013), or 
association of health-outcome (National Toxicology Program 2013b). 
 Custom visualization for displaying a point-of-departure and reference value, 
including details on the underlying data and assumptions for derivation. 
 Users should be able to create their own custom visualizations of quantitative data 
which again, allows interlinking of key components of database to access details. 
 Commenting should be enabled on any type of object contained in the database, 
from a chapter in the summary text to a specific endpoint. 
 Commenting can be enabled or disabled at the assessment-level, along with 
detailed moderation tools to triage comments, track responses, and archive 
comments as content changes 
Prototypical implementation 
A database schema was constructed presenting key components of the summary 
modules, and is presented below in Figure 32. A total of 6 primary tables were created 
(with one abstract relationship, DataPivot). The primary structure used for storing 
summary text is the Summary object. Each Summary is a section of a document, including 
both the header and text. In the database, these are organized using the MPTT database 
pattern (previously described in the Literature Review Module), allowing sections of a 
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Summary to have a single parent and optionally multiple children.  Therefore, a traditional 
document structure can be obtained, with each section a distinct entity (which is useful 
for commenting on a specific section of a report). The Summary-text also includes a 
built-in feature custom to HAWC name SmartTags. These tags, further described in the 
evaluation section below, allow a user to create inline visualizations or popup boxes 
which provide further details to a particular item. For example, a SmartTag may be added 
to show the dose-response details for a particular endpoint, or to display risk-of-bias 
details for a particular study.  
In addition to textual summaries, DataPivot items were created to allow users to 
query available data in an assessment and build custom visualizations. Two types of 
DataPivot objects can be created- one which interactively uses data stored in other 
modules of the assessment (DataPivotQuery), and one which includes an uploaded tab-
delimited text-file of data to present (DataPivotUpload). The DataPivot functionality is 
described below in the Data Pivot section. 
Finally, a Comment table was created, which allows for custom annotation of 
objects of any type, if the assessment is currently enabled for commenting in the 
CommentSettings. If enabled, any logged-in user will be able to create comments to any 
item in an assessment, from a particular study, an experimental design, an animal 
bioassay endpoint, or a specific section or subsection of the summary text. 
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Figure 32: HAWC summary modules database schema. 
 
 
A summary of how the requirements described above align with the HAWC 





Summary text can be created and 
organized in hierarchical format Fully  
Integration of data and visualizations in 
summary reports from other modules Fully  
Summary text can be downloaded in 
Microsoft Word format Fully  




May require additional tables for hazard bins 
and custom display logic 
Visualization for displaying reference 
value and underlying data Fully Created within the animal bioassay module 
Custom visualization for displaying 
multiple endpoints Fully 
Endpoint aggregation, data pivot,  and 
crossview plots 
Commenting for individual objects 
within an assessment Fully  
Commenting enabled or disabled at the 
assessment-level, with moderation tools 
for tracking Partially 
Commenting currently can be enabled or 
disabled, but no moderation tools available 
Table 12: Summary module requirements and implementation in the HAWC prototype.  
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Data Pivot 
One critical requirement in drafting a health assessment is the evaluation of a 
related set of endpoints, and discussing the relative magnitude of effect, along with other 
factors which may be associated with an adverse effect. The creation of a Forest-Plot is 
frequently used to convey this information. In HAWC, a visualization known as the Data 
Pivot was created to allow for customizable forest-plots to display a set of related data; 
the concept was originally adapted from the MetaData Viewer software designed to view 
epidemiological data (Boyles et al. 2011).  An example data divot is shown in Figure 33, 
displaying carcinogenic effects from the Nitrofen assessment.  
Figure 33: Example data-pivot from Nitrofen assessment, displaying tumors and other carcinogenic effects 
found identified from NCI 1979. Sorting, filtering, ordering, and column presentation are all fully 
customizable. In addition, plots are interactive, linking to other data in HAWC. The example below 
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The Data Pivot imports all animal bioassay or epidemiological data currently 
available in a HAWC assessment, and the display is fully customizable. A user can sort, 
filter, stylize, and re-order endpoint-level data in the assessment for presentation. They 
can also choose which textual columns to present, as well as identify threshold values on 
the chart. One key advantage of use of the web-based interface as opposed static 
document is the fact that links between data and relationships can be preserved and 
presented.  As an example, Figure 33 above links the data pivot with details on study 
summaries and dose-response data. For epidemiological datasets, details on the study 
population can also be presented in addition to endpoint level details. 
Crossview 
One additional visualization was created to demonstrate the advantages to storing 
dose-response data for a chemical risk assessment in a relational database, which was not 
shown in the database schema (as no additional data-storage is required). The Crossview 
plot, shown below in Figure 34, presents all bioassay dose-response endpoints extracted 
for an assessment in a single visualization. The plot is interactive; key attributes of data 
presented are shown on the right, and by hovering over a dose-response curve its 
corresponding attributes are also highlighted. The converse is also true; by hovering over 
an attribute, all dose-response curves which contain this attribute are highlighted. 
  
Chapter 4: Results 
90 
Figure 34: Crossview visualization displaying all animal bioassay dose-response data available in the 
Nitrofen assessment. Each individual line represents one dose-response dataset; lines are based on 
spline-interpolation of summary dose-response data. Continuous data are normalized to the relative 
change with respect to control; dichotomous data are presented as fraction incidence. Key metadata 
associated with each individual dataset are shown on the right; characteristics shown in red indicate that 
the current user is interacting with the plot and has selected an endpoint in red with the following 
characteristics. The insert demonstrates an additional interactive feature- the insert shows example of 
dynamic display of endpoints selected in red, with hyperlinks to view further details at the top of the 
popup. Live example. 
 
 
By visualizing all data on a single plot, this may aid the user in detecting outliers 
of effect, or evidence gaps where little data are available.  For example, in the example 
above, the highlighted endpoint presents a change in response at a dose lower than all 
other endpoints in the analysis. In addition, it is also the only endpoint with 
“developmental” or “hernia” tags associated. This may lead a reviewer to conclude that 
this chemical may be cause developmental effects at lower doses, but also that data 
related to hernia developmental effects are limited in the database. While this certainly 
could be determined from evidence tables or a textual paragraph, the use of a visual 
display may help aid a user to quickly identify trends or clear outliers. 
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Evaluation 
The original PPRTV Nitrofen document was recreated in HAWC using the 
summary text-module. Studies and effects which were described in the textual summary 
available in the HAWC database were included and SmartTags were inserted (which 
allow for easy access to viewing underlying data associated with these tags). To date, 
smart-tags can be included for study information (which displays study data, summary, 
and systematic review data), endpoint information (which displays animal bioassay or 
epidemiological data), data-pivots (which displays custom-created data pivots) and 
endpoint aggregations (collections of animal bioassay endpoints).  Figure 35 below 
presents an example view of the summary text, related to the derivation of the Nitrofen 
oral reference values.  The use of SmartTags allowed for a substantial reduction in text, 
as more detailed information was available to readers by clicking on SmartTags. 
Figure 35: Summary-text findings from the Nitrofen assessment. Note that items highlighted in blue are 
SmartTags and are interactive; selecting a tag will reveal a popup box with further details related to the 
selected item. This is an alternative to directing a user to the appendix to a specific data-table or endpoint 
description, and utilizes the relational database structure of the HAWC framework. Hyperlink. 
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The BPA obseogen project is still a work-in progress, and therefore no summary 
text has yet been created. However, the Data Pivot feature has been utilized to synthesize 
key findings of the epidemiological data currently contained in the database.  Figure 36 
presents a summary of obseity-related outcomes in children and adult populations in the 
CDC National Health and Nutrition Examination Survey (NHANES).  
Figure 36: Data pivot presenting weight-related effects from the NHANES survey in children and adult 
populations. Three outcomes were assessed, metabolic syndrome (MetS), elevated waist circumference, 
and obesity.  Details on study and risk of bias, study-population, and assessed-outcome details are 

















Finally, as an example of release of an assessment to the public or peer review, 
Figure 37 demonstrates the addition of comments to specific assessment items. The 
example below is presented for the Nitrofen assessment, and includes hypothetical 
comments applied to studies, the assessment overall, and a specific subsection of the 
summary text. Note that comments created were not based on public comments for 
Nitrofen or any other assessment, and are used for demonstration purposes of the ability 
to add comments to individual objects in an assessment. 
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Figure 37: Example comment-summary presented for a collection of objects in the Nitrofen assessment. 
Comments have been added to sections of the summary text, the overall assessment, and a study. These 
comments are currently public and commenting has been enabled for this assessment. Live example. 
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External outreach and website use 
A series of online webinars were performed in early 2014 after a majority of the 
prototypical modules were complete. A total of 104 callers attended two webinars open to 
the public and released from the NTP listserv; a screencast of the webinar and basic 
training on HAWC functionality is available online here. In addition to Webinars open to 
the public, two additional teleconferences were performed for the International Agency 
for Research on Carcinogens (IARC) and the European Food Safety Authority (EFSA). 
To date 73 users have registered for the HAWC website (April 13, 2014). A total of 30 
assessments have been created (April 12, 2014). A summary of key statistics for website 
















January (1-31) 3,801 247 02:08 00:21:07 10 24.8 
February (1-28) 2,737 100 02:01 00:27:54 9 96.1 
March (1-31) 3,295 90 02:47 00:44:59 3 130.0 
April (1-12) 1,199 41 04:25 01:15:54 0 130.3 
Total  11,032 478 N/A N/A 22 N/A 
Table 13: Summary of key statistics for HAWC since from January 1, 2014- April 13, 2014. Statistics for 
page-views, visitor-count, and time-spent on page were calculated automatically by Google Analytics. 
Data for assessments created from database analysis from HAWC website. Database size calculated from 
daily-database backup files, uncompressed file-size. 
 
A total of 11,000 pages have been viewed on HAWC since over a period of 
approximately 3.5 months. Nearly 500 unique visitors have viewed the website. The total 
page-view count and unique visitors have decreased over time, but the average time spent 
on page and visit-duration has increased. Thus, appears to indicate that fewer users are 
“bouncing” form the site, and are spending more time on each page. The number of 
assessments being created has decreased, but overall database-size in increasing, 
indicating that new data is being added to each assessment. 
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Chapter 5: 
Discussion, Limitations, Conclusions, and Future Directions 
Discussion 
The human health assessment of chemicals is an inherently complex process, 
requiring synthesis or large amounts of data of varying types and quality, and then 
performing a detailed analysis to draw conclusions on the overall safety of a chemical. 
Recent critiques of the approach have requested greater transparency, quality, and speed 
with which these assessments can be completed (Gray and Cohen 2012; National 
Research Council 2011). Methods have been proposed to improve the quality of these 
assessments, such as literature  review tracking (Kushman et al. 2013) and tagging of 
included or excluded studies, and the systematic review of studies (National Toxicology 
Program 2013a), but these approaches are frequently more data-intensive and require 
further documentation. Finally, the quantity of next-gen in-vitro data has increased 
exponentially in recent years, and new techniques have been proposed to integrate these 
data into current assessments (Crump et al. 2010; Thomas et al. 2013; Judson et al. 2011).  
Given the stress of the current process, and the added stress expected given new 
data and methods in the future, we attempted to reformulate how a human health 
assessment may be conducted, by utilizing an online content-management system 
designed for these assessments. A modular framework for such a software system was 
proposed, along with a detailed list of software and data requirements for each module. 
Further, a prototype of the software was develop is publically available at 
https://hawcproject.org. In an effort to evaluate the prototypical system, a key data and 
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conclusions from a final assessment were entered into the application. In addition, data 
from an ongoing assessment was also entered into the software to evaluate performance 
for an ongoing assessment. 
Interest in a software solution 
There is clear interest for a software solution which can help to the creation of 
these human health assessments of chemicals. Over one-hundred people attend the 
webinars for the presentation of the HAWC software. Further, from January 1-April 12, 
over 478 unique visitors have accessed the website, visiting a total of 11,032 webpages. 
Over 70 individuals have created user accounts, and 30 assessments have been created.  
The software is actively being used for the development of a few key assessments 
of interest. Three assessments are actively being developed currently in partnership with 
the National Toxicology Program Office of Health Assessment Translation (NTP/OHAT) 
using the HAWC software. In addition, the California OEHHA is also currently utilizing 
the HAWC tool for its literature search and reviews. Further, discussions are currently 
being had with the IARC assessment protocol for utilizing HAWC for components of 
these assessments.  This indicates clear external interest in a software solution that may 
help users conduct and document these assessments. 
Despite not all requirements being met, a usable prototype exists 
Each module included a number of functional requirements, many of which were 
not fully or even partially implemented in the prototypical software application. Most 
requirements were not achieved due to a lack of time, not because of any technical or 
philosophical implementation roadblocks. Despite the fact that these requirements were 
not all achieved, in the end, a functional system was completed that did allow accurate 
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representation of the chemical assessments. Further expansion of the existing modules 
may add additional functionality and improve usability, as well as improve the 
underlying process of assessment creation. One key area that may need improvement in 
the current software system is updating the design to allow for quality assurance and 
quality control of the data.  
The time and effort spent for development of the prototype was not trivial; over 
40,000 lines of code were written over two-years for the project, resulting in a unique 
software application unlike any other we are aware of. However, this was the work of a 
single graduate student. Development of a production-ready system would certainly 
require more resources, but may be within reason for a regulatory agency. 
Most of the data from the Nitrofen PPRTV could be captured 
Key modules in the HAWC assessment were developed using the IRIS preamble 
document, as well as discussions with collaborators.  In order to test the functionality of 
the modules being added, actual content from real datasets were entered as these modules 
were being developed.  An overwhelming majority of the animal bioassay data which 
was presented in the Nitrofen assessment was able to be stored and presented in the 
HAWC prototype application. Benchmark dose-modeling which was also recompleted, 
and results were replicated exactly to those calculated in the original assessment. 
Implementation of the benchmark dose software may be revisited in the future however, 
as differences in results were observed, particularly for continuous models, using the 
recompiled versions of the software.  Finally, the provisional reference values derived 
and could be captured in the relational database and through web views, including the 
point of departure and uncertainty factors applied. 
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Most, but not all, of the animal bioassay data which was presented in the Nitrofen 
assessment was able to be captured using the animal bioassay database schema. One 
dataset, specifically a repeated response measurement over time, could not be entered 
into the database preserving response-relationships across time-point. Despite this fact, it 
was included in the summary-text, and key time periods could also have been captured as 
individual endpoints. Therefore, despite the fact that the data could not be captured 
accurately in the database, the findings were able to be summarized in the summary-text 
module and therefore could be applied to the conclusions of the human health 
assessment.  
This is an example where the strength of the entire prototype may be greater than 
the sum of the individual modules. If a database alone existed to capture animal bioassay 
information, then a limitation in the database schema may force data to be excluded and 
potentially omitted from the conclusions of an assessment. However, the summary 
module did allow for further details to be captured, and key data could still be included.  
While not ideal, this implementation is equivalent to current practices for human health 
assessment documentation, by entering data in a free-text form. Other assessments may 
be limited by other datastreams which cannot be captured using the current structure, but 
by utilizing the summary module, these data still have the potential to be captured. 
The creation of a relational database for animal bioassay and epidemiological data 
for integration into the HAWC assessment will require more time to enter the published 
data into a relational database structure. However, much of that time is already spent in 
the manual construction of evidence tables in documents. The added advantage of 
entering the data into a database may allow for easier reanalysis as the conclusions of 
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assessment change, additional data become available, or as the research questions may 
evolve with additional analysis. Further, data-sharing would be possible for reviewers or 
for future analysis by other parties, which is simply not possible with the current 
document-based assessments produced by regulators.  By developing a database backend 
and web-application framework for interaction with the data dynamically, future 
assessments including high-throughput in vitro data may be easier to integrate into the 
current assessments, since a prototypical software framework already exists. 
Finally, key critiques of recent IRIS assessments include a lack of transparency in 
the determination of which data were used, and what decisions were made to select a 
subset of the data for reference-value derivation. At the same, it was also recommended 
to reduce the size of these documents.  The Nitrofen assessment as presented in the 
HAWC prototype is one example of how this might be possible. They summary views 
contained much of the text which was originally presented in the original documentation. 
However, the text is much shorter that what was originally prepared. Study summaries 
are still present, though they were moved to the study modules and therefore can be 
viewed by utilizing the SmartTags if a reviewer may be interested in more details. 
Further, endpoint data presented in the appendices were all available, and also allowed 
the text to be more specific as to which endpoints were being used in different sections of 
the text.  In some ways, the HAWC prototype may be thought of as providing an 
executive summary (the summary-text), with interactive appendices being available by 
browsing the assessment database, as rendered on the website. Should raw-data be of 
interest to a reviewer, it can be downloaded, something which is simply not possible with 
document-based solutions. 
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Using HAWC for analysis is currently limited but can be improved 
Much of the work currently performed for development of the HAWC prototype 
was focused primarily on data entry and simple visualization of the data entered. This is 
consistent with the fact that one of the test assessments used (Nitrofen) was a completed 
assessment, and therefore results presentation, instead of analysis, was of interest. The 
other analysis used for testing is the ongoing BPA obesity assessment, which is not yet 
completed. To that end, analysis tools such as the data pivot, Crossview, and data exports 
were created, but much significantly-more would could be performed to allow for better 
analysis of the data currently in the database. 
Limitations 
Selection of modules themselves, as well as all requirements for the creation of a 
content management system, are subject to the author's interpretations of priorities and 
requirements for the development of human health assessment of chemicals. These 
decisions were based on literature and discussions with experts, but they are open for 
debate. Second, not all requirements were able to be implemented in the prototype 
software modules. Being unable to complete implementation was largely due to a lack of 
staff, though it may be possible that some requirements may be difficult to implement in 
the prototypical framework. One key requirement not implemented in any module is a 
method for identifying QA/QC of data which has been entered. Therefore, the quality of 
data entered on the tool is solely dependent on the data-entry methods decided upon by 
each assessment-team. 
Next, the prototype software system developed was unable to capture all types of 
data which may be of potential use for human health assessments, nor even all the data 
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used for our test assessment. Examples include the multiple time-response measurements 
from the Nitrofen assessment. It is unlikely that any system may be able to capture the 
amount of variability that is present, though improvements to the current prototype could 
certainly be made. Therefore, to account for this, flexibility in the summary reporting and 
the ability to add free-text and tables should be allowed. Adding additional flexibility is a 
balancing act as inclusion of data in free text in some ways violates the philosophy of the 
content management system, but it is required to allow expert judgment to prevail.  
Second, current functionality of the HAWC prototype is limited. Some issues can 
be overcome by additional development of new features, such as adding additional design 
and customization of visualizations, or adding additional functionality for further 
customization of output tables and reports. These may require additional time and 
financial resources, but would allow reusability on any assessment in HAWC. However, 
there are technological limitations associated with any platform selected; it is unlikely 
that the flexibility of a traditional document-based report will ever be realized in a 
management system.  This is both a benefit and detriment to the current document-based 
risk assessments are their flexibility; while use of a document does allow for greater 
flexibility, using a content-management system allows automation for many tables and 
figures, which may save time and cost in the future.  
Third, the additional time and cost of the data entry required for use of such a 
system is an important variable. As described previously, there is certainly a cost 
associated with the added data entry. However, it may also be the case that these costs are 
incurred upfront and there may be a reduction of time spent in analysis, documentation, 
reanalysis, or other components of the human health assessment process.  
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Finally, the current implementation of the prototype includes simple-tags for 
categorization of epidemiology and animal bioassay endpoints into organs, biological-
systems, and/or related effects. The current implementation allows for an infinite number 
of tags to be created in no hierarchical order. Therefore, endpoints tagging is highly 
subjective and based on an individual’s personal preferences, and doesn’t preserve any 
semantic processing power.  The use of an existing ontology for identification of 
endpoints may allow for better understanding relations between endpoints, including 
those from different datastreams (bioassay, epidemiology, and potentially in vitro). 
Conclusions 
We have identified software requirements for the human health assessment of 
chemicals and developed a prototypical software application based on these 
requirements.  Both a database schema which can capture much of the data and decisions 
made for such an assessment and a user-interface were designed. Considerations were 
made for both team-members in creating the assessment and for the final public display 
and evaluation of the conclusions, including the ability for export of data for additional 
analysis. Two existing assessments were used for testing the database and interface 
design.  Most, but not all, of the data used to complete the assessment were able to be 
captured in the relational database structure. Further, a similar textual summary was able 
capture the main findings of the assessment, but with added ability to dive into further 
details by utilizing the database and web-technologies for visualization and data display. 
In addition to the creation of content-management system for capturing current 
assessments, additional modules were designed based on recommendations for 
improvement of current assessments, such as the additional of literature tagging and 
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review and the systematic review to identify risk of bias.  To our knowledge, this is the 
first time that an application has been developed to capture and present the data and 
findings from the human-health assessment of chemicals, from literature search to 
reference value derivation. We hope that this this may be able to inform future scientists 
and developers, in their attempt to integrate next-generation datastreams into human-
health assessments using a data-driven approach. 
Future Directions 
Future directions for include continued development on the current prototype to 
expand analysis and reporting functionality. This would include many mundane changes 
such as designing object-versioning (i.e. track-changes) views to many objects in an 
assessment, or improving tabular- or report-based downloads.  While not necessarily an 
interesting research goal, it would be an important step to fully utilize the current 
prototypical application created. In a similar vein, much could be done to improve the 
stability of the software and the overall codebase by significant refactoring or the design. 
Further, despite our best attempts at keeping modules independent of one-another, there 
was some bleed-over. For example, the study and study-quality module depends highly 
on the literature-search module for creation of a reference. In addition, the animal 
bioassay module allows for creation of a reference value using animal bioassay data, but 
the epidemiological module does not. Refactoring the prototypical modules would be a 
valuable process, and would allow for easier integration of new modules, such as the in-
vitro module currently under development. This may also allow for easier third-party 
usage and data-sharing capabilities. 
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A key-area of further research is incorporation of in in vitro data. In many 
currently produced assessments such as the IARC process, the results of genotoxic or 
cytogenic assays are included for corroboration of observed phenotypic effects. Design of 
the appropriate database schemas to capture this data, as well as intuitive user-
interactions with these data, would be important to replicate the current IARC process. 
Further, incorporation of high-throughput screening data from external databases, and 
developing a module for hazard characterization using the IVIVE methodology would 
also expand the scope significantly for the type of chemicals for which a health 
assessment could be conducted.  
Further research on the creation or utilization descriptive endpoint ontologies 
could be used instead of the tagging approach currently used in the prototype.  Existing 
controlled vocabularies for bioassays (Martin et al. 2009) could be used, though it may 
require adaption to account for epidemiological and in vitro data as well. This could also 
allow better utilization of the in vitro data, as many assays are designed to target 
components of biological pathways which may lead to downstream phenotypic 
responses. Further, it may be beneficial in the integration of bioassay, epidemiological, 
and mechanistic datastreams, and for applying additional approaches where mechanistic 
data can be captured, such as adverse outcome pathways (AOPs), or others. 
Finally, the current framework is limited in that only some types of data can be 
captured, such as the inability to capture the multiple response measurements over time 
data in the Nitrofen assessment. In addition to schema issues previously described, this 
due in part to limitations of a relational database, which requires the predefinition of 
tables, fields, and their relations. Use of a document-oriented database, such as 
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MongoDB, could eliminate the hard-requirement of predefined data schemas. However, 
it may also complicate the design of effective views or reporting mechanisms, making 
this another interesting area for further research. 
 




I completed my public health practicum experience at the US Environmental 
Protection Agency, working with the National Center for Environmental Assessment 
(EPA/NCEA) in Research Triangle Park, North Carolina. EPA/NCEA’s main-role is to 
provide guidance for how pollutants may impact health and the environment, by 
conducting human-health risk assessments and hazard characterizations such as the 
Integrated Risk and Information System (IRIS) reports (U. S. EPA 2014e). EPA/NCEA is 
one of thirteen divisions under the EPA Office of Research and Development (ORD). 
While working there, I had the opportunity to work with professionals in working in the 
Hazardous Pollutant Assessment Group, led by current Acting Director, Dr. Lyle 
Burgoon, as well as staff working under the Human Health Risk Assessment Research 
Program, led by Dr. John Vandenberg. Specifically, I worked for Dr. Jeff Gift, who is 
involved in the development of IRIS assessments and as the project manager for the 
Benchmark Dose Modeling Software (BMDS) maintained by EPA/NCEA (Davis et al. 
2011). 
I had many goals while working at EPA/NCEA, the first of which was getting 
hands-on experience on-site with governmental research staff. Next, I wanted to work 
with the group in developing the latest version of the BMDS software, and learn more 
about the benchmark dose-modeling methods currently under development. Finally, the 
EPA/NCEA is a primary producer of chemical risk assessments in the federal 
government. Therefore, I hoped to learn more about the process and requirements for 
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producing IRIS assessments. This includes a better understanding of use-cases, user-
requirements, and potential issues in the creation of an effective content-management 
system for producing health-assessments of chemicals. 
I learned a great deal about the benchmark dose model-averaging techniques.  In 
the conventional approach, as was implemented in the HAWC research project, one 
model was selected as the best-fitting model after running a suite of different model 
forms on the same set of dose-response data. The model selection process is well 
documented (U. S. EPA 2012a), but essentially recommends select a well-fitting, 
parsimonious model (using Akaike’s Information Criteria, or AIC). Some argue that by 
selecting only one-best fitting model, models which may have additional information 
regarding the true-dose relationship are discarded (Shao and Gift 2013). To account for 
this, methods currently being developed may compute a model-average BMD estimate, 
using a weighted average based on model performance. The Shao and Gift 2013 paper 
suggests a Bayesian model averaging technique and compares estimation methods using 
maximum likelihood estimation (MLE) or Monte-Carlo Markov Chain (MCMC) 
methods. For estimating the benchmark dose lower-limit (BMDL), a value of importance 
in risk assessment as it is often selected as a point-of-departure, bootstrapping is applied, 
and the model fit and averaging are repeated, and the BMD realization at the specified 
percentile for lower-confidence is selected as the BMDL. 
I assisted EPA/NCEA in comparing different proposed methods for model 
averaging by assisting in software development of prototypes for method comparison. 
The work involved reading recent papers presenting the approaches, including a paper 
which included a comparative analysis (Shao and Gift 2013). I helped to design a 
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pipeline to integrate source-code to perform a bootstrap for BMDL estimation (written in 
C++) from Wheeler and Bailer 2007 into a variant of the BMDS software for testing 
(written in C#).  I modified code to call the Bayesian modeling averaging model 
subroutine, and implemented features intended to view the output report, extract 
information into an Excel report, and added new inputs and interface changes from the 
discussions with the team. In doing so, I learned more about team-software development 
practices at the EPA, as well as the modeling methods which were implemented into the 
software. 
Working with the staff at EPA/NCEA was important to better understand the 
user-requirements and use-cases for the software created for my technical report. The 
IRIS team is one key set of potential users for the HAWC software, so understanding 
how the team operates may improve the usefulness of the HAWC software. In particular, 
one module implemented in HAWC utilizes the BMDS modeling software. Discussions 
with the BMDS team at EPA lead to interface changes for the HAWC BMDS module. In 
addition, the latest version of the BMDS software (version 2.40), was implemented 
during my time spent at the practicum, at the request of the EPA/NCEA team. Finally, 
integration of the HAWC software and the EPA’s Health and Environmental Research 
Online (HERO) database were also discussed during my time at the practicum. The 
HERO database contains literature for all references in NCEA assessments, but does not 
currently contain any quantitative bioassay or epidemiological information from study-
extraction. Though these discussions, I helped the HERO team in developing 
requirements for an application programming interface (API) so that software such as 
HAWC could communicate to the HERO database. Development of an API was already 
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a stretch goal for the HERO development team at the EPA, and the potential of HAWC 
as a user helped to define the need for this feature. The API was later utilized by the 
HAWC website (as described in Literature Review Module). I worked closely with the 
HERO team during this period in developing requirements for the API as a consumer, as 
well as discussions for how quantitative data can be incorporated into the HERO database 
in the future. 
During my practicum experience, I achieved the following competencies laid out 
by the Gillings School of Global Public Health and Department of Environmental 
Sciences and Engineering: 
 
Communication and Informatics 
 Use information technology tools effectively in core public health functions such 
as retrieval of institutional and online public health data and dissemination of 
public health information. 
 Engage in collective information sharing, discussion and problem solving. 
 
Diversity and Cultural Competency 
 Show effective and productive skills in working with diverse individuals 
including co-workers, partners, stakeholders, and/or clients. 
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Leadership 
 Create a climate of trust, transparency, mutual cooperation, continuous learning, 
and openness for suggestion and input with co-workers, partners, other 
stakeholders, and/or clients. 
 Exercise productive organizational, time-management and administrative skills. 
 Develop knowledge of one’s individual strengths and challenges, as well as 
mechanisms for continued personal and professional development. 
 
Professionalism and Ethics 
 Review, integrate, and apply ethical and/or legal principles in both personal and 
professional interactions, as well as public health practice and/or research. 
 Appreciate the need for lifelong learning in the field of public health. 
 
Program Planning 
 Discuss social, behavioral, environmental, and biological factors that contribute to 
specific individual and community health outcomes. 
 Identify needed resources for public health programs or research. 
 
Systems Thinking 
 Identify characteristics of a system. 
 Respond to identified public health needs within their appropriate contextual 
setting. 
 Interpret the results addressing the strengths and limitations of the inference(s). 
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Environmental Sciences Competencies 
 Describe the direct and indirect human, ecological and safety effects of major 
environmental and occupational agents. 
 Describe federal and state regulatory programs, guidelines and authorities that 
control environmental health issues. 
 Specify current environmental risk assessment methods. 
 Specify approaches for assessing, preventing and controlling environmental 
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Appendix 1: HAWC License 
UNC-CH Software Health Assessment Workspace Collaborative (HAWC)  
Copyright (C) 2013 The University of North Carolina at Chapel Hill  
All rights reserved. 
 
The University of North Carolina at Chapel Hill (“UNC-CH”) and Andy 
Shapiro, Seyi Idowu, and Ivan Rusyn, the developers (“Developers”) of 
UNC-CH Software Health Assessment Workspace Collaborative (HAWC) 
(“Software”) give recipient (“Recipient”) and Recipient’s Institution 
(“Institution”) permission to use the software in source and binary 
forms, with or without modification for any purposes provided that the 
following conditions are met:  
 
All copies of Software in binary form and/or source code, related 
documentation and/or other materials provided with the Software must 
reproduce and retain the above copyright notice, this list of 
conditions and the following disclaimer. 
 
Recipient shall have the right to copy or create modifications of the 
Software (“Modifications”) for their internal research and non-profit 
purposes only. 
 
All copies of Modifications in binary form and/or source code and 
related documentation must reproduce and retain the above copyright 
notice, this list of conditions and the following disclaimer. 
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Recipient and Institution shall not distribute Software or 
Modifications to any third parties without the prior written approval 
of UNC-CH. 
 
Recipient may provide the Developers with feedback on the use of the 
Software and Modifications, if any, in their research. The Developers 
and UNC-CH are permitted to use any information Recipient provides in 
making changes to the Software. All feedback, bug reports and technical 
questions shall be sent to: 
 
Ivan Rusyn, iir@unc.edu, P: (919) 843-2597 
Andy Shapiro, ajshapir@email.unc.edu, P: (919) 417-1475 
 
Recipient acknowledges that the Developers, UNC-CH and its licensees 
may develop modifications to Software that may be substantially similar 
to Recipient’s modifications of Software, and that the Developers, UNC-
CH and its licensees shall not be constrained in any way by Recipient 
in UNC-CH’s or its licensees’ use or management of such modifications. 
Recipient acknowledges the right of the Developers and UNC-CH to 
prepare and publish modifications to Software that may be substantially 
similar or functionally equivalent to your modifications and 
improvements, and if Recipient or Institution obtains patent protection 
for any modification or improvement to Software, Recipient and 
Institution agree not to allege or enjoin infringement of their patent 
by the Developers, UNC-CH or any of UNC-CH’s licensees obtaining 
modifications or improvements to Software from the UNC-CH or the 
Developers. 
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Recipient and Developers will acknowledge in their respective 
publications the contributions made to each other’s research involving 
or based on the Software. 
Any party desiring a license to distribute, modify, or offer the 
Software and/or Modifications for commercial purposes shall contact The 
Office of Technology Development at UNC-CH at 919-966-3929. (Ref # UNC 
13-0134) 
 
THIS SOFTWARE IS PROVIDED BY THE COPYRIGHT HOLDERS, CONTRIBUTORS, AND 
THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL "AS IS" AND ANY EXPRESS 
OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, THE IMPLIED 
WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE ARE 
DISCLAIMED. IN NO EVENT SHALL THE COPYRIGHT OWNER, CONTRIBUTORS OR THE 
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL BE LIABLE FOR ANY DIRECT, 
INDIRECT, INCIDENTAL, SPECIAL, EXEMPLARY, OR CONSEQUENTIAL DAMAGES 
(INCLUDING, BUT NOT LIMITED TO, PROCUREMENT OF SUBSTITUTE GOODS OR 
SERVICES; LOSS OF USE, DATA, OR PROFITS; OR BUSINESS INTERRUPTION) 
HOWEVER CAUSED AND ON ANY THEORY OF LIABILITY, WHETHER IN CONTRACT, 
STRICT LIABILITY, OR TORT (INCLUDING NEGLIGENCE OR OTHERWISE) ARISING 
IN ANY WAY OUT OF THE USE OF THIS SOFTWARE, EVEN IF ADVISED OF THE 
POSSIBILITY OF SUCH DAMAGE.
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Appendix 2: HAWC Source Code  




Note that the source-code may change and continue to be updated after the submission of 
this technical report; therefore the features discussed and implemented as presented may 
not be consistent with more recent versions, should development continue. Therefore, a 
compressed zip-file containing all source-code at the time of writing is also available in 




To find, search for the author’s name, “Andrew Shapiro”, and a digital-copy of this 
technical report as well as the source code should be available. 
